

## Scientific Programme

### Sunday, 22 March 2020

---

Non-Profit Symposium  
08:30 - 10:00

N103

#### **IS1, How does MRD impact outcome of stem cell transplantation in AML, now and in the future? - AML Hub non-profit symposium**

Non-Profit Symposium  
08:30 - 10:00

Hall A (Exhibition Area)

#### **IS2, Dilemma in allogeneic hematopoietic transplantation for myelofibrosis - Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) non-profit symposium**

Non-Profit Symposium  
08:30 - 10:00

Hall B (Exhibition Area)

#### **IS3, Latest developments in hematopoietic cell transplantation - Sorbonne University (ATERHIT) non-profit symposium**

##### **Chairs:**

Arnon Nagler (Israel)

Bipin Savani (United States)

<b>Haplo transplant for AML</b>	<b>08:30 - 08:45</b>
Arnon Nagler (Israel)	
<b>Haplo transplant for the elderly</b>	<b>08:45 - 09:00</b>
Didier Blaise (France)	
<b>Monoclonal antibodies in ALL</b>	<b>09:00 - 09:15</b>
Eolia Brissot (France)	
<b>Monoclonal antibodies in Hodgkin lymphoma</b>	<b>09:15 - 09:30</b>
Ali Bazarbachi (Lebanon)	
<b>Allogeneic transplantation after CAR T-cell therapy</b>	<b>09:30 - 09:45</b>
Bipin Savani (United States)	
<b>Round table discussion</b>	<b>09:45 - 10:00</b>

## Scientific Programme

Non-Profit Symposium  
08:30 - 10:00

N105

### IS4, Multiple Myeloma in 2020: The IFM global perspective - IFM non-profit symposium

**Chairs:**

Mohamad Mohty (France)  
Jean-Luc Harousseau (France)

<b>What's new for induction prior to ASCT?</b> Philippe Moreau (France)	<b>08:30 - 08:50</b>
<b>What's new in the elderly setting?</b> Thierry Facon (France)	<b>08:50 - 09:10</b>
<b>Monoclonal antibodies for relapse after ASCT</b> Mohamad Mohty (France)	<b>09:10 - 09:30</b>
<b>Requirements for functional cure in myeloma</b> Jean-Luc Harousseau (France)	<b>09:30 - 09:50</b>
<b>Round table discussion</b>	<b>09:50 - 10:00</b>

CME Symposium  
08:30 - 10:00

Sala Retiro

### IS5, GMMG CME Symposium: Stem cell transplantation in Multiple Myeloma

**Chairs:**

Hartmut Goldschmidt (Germany)  
Hans Salwender (Germany)

<b>Role of allo-TPX in Multiple Myeloma</b> Nicolaus Kröger (Germany)	<b>08:30 - 08:45</b>
<b>Impact of age on the decision of auto-TPX in Multiple Myeloma</b> Hans Salwender (Germany)	<b>08:45 - 09:00</b>
<b>Predictive factors in Multiple Myeloma</b> Hartmut Goldschmidt (Germany)	<b>09:00 - 09:15</b>
<b>Treatment of high-risk Multiple Myeloma</b> Katja Weisel (Germany)	<b>09:15 - 09:30</b>
<b>Role of antibodies in the treatment of Multiple Myeloma</b> Igor-Wolfgang Blau (Germany)	<b>09:30 - 09:45</b>
<b>Cellular Therapy in Multiple Myeloma</b> Christoph Scheid (Germany)	<b>09:45 - 10:00</b>

## Scientific Programme

Nurses Group  
08:30 - 10:00

Sala Colón

### **NG01, Nurses Education Day: Steroids - The haematology bad boys. Love them, loathe them, can't live without them**

#### **Chairs:**

Caroline Bompont (France)  
Julia Ruiz (Spain)

<b>Welcome and introduction</b> John Murray (United Kingdom)	<b>08:30 - 08:35</b>
<b>Overview: Indications and implications</b> Jörg Halter (Switzerland)	<b>08:35 - 09:00</b>
<b>How does it work? Mechanims of action</b> Agnès Bonnin (France)	<b>09:00 - 09:30</b>
<b>Use in paediatrics</b> Alberto Castagna (Italy)	<b>09:30 - 10:00</b>

EBMT Exam  
09:00 - 12:00

Sala Neptuno

### **EBMT Exam**

Statistics  
09:00 - 12:00

N117

### **Stat1, Statistical Course: Basic Statistics**

<b>Basic Statistics</b> Antonella Santucci (Italy) Richard Szydlo (United Kingdom)	<b>09:00 - 12:00</b>
--	----------------------

Patient, Family Donor Day  
09:15 - 09:30

N101

### **PFD0, Patient, Family and Donor Day: Welcome**

#### **Chairs:**

Bregje Verhoeven (Netherlands)  
Lola Manterola (Spain)

<b>Welcome from Madrid</b> Rafael Duarte (Spain)	<b>09:15 - 09:20</b>
<b>Welcome from Patient Advocacy Committee</b> Bregje Verhoeven (Netherlands)	<b>09:20 - 09:25</b>

## Scientific Programme

**Housekeeping** 09:25 - 09:30  
Lola Manterola (Spain)

Patient, Family Donor Day 09:30 - 11:00 N101

### **PFD1, Patient, Family and Donor Day: General introduction**

#### **Chairs:**

Guy Bouguet (France)  
Lola Manterola (Spain)

**My Experience with cGVHD** 09:30 - 09:40

**Overview of hematopoietic stem cell transplantation** 09:40 - 10:10  
Miguel Ángel Díaz Pérez (Spain)

**Chronic GVHD: The Daily Impact** 10:10 - 10:40  
Régis Peffault de Latour (France)

**Questions & Answers** 10:40 - 11:00

Industry Symposium 10:30 - 12:00 N103

### **IS6, GVHD: What's new in 2020? - Sanofi Genzyme Industry Symposium**

Industry Symposium 10:30 - 12:00 Hall A (Exhibition Area)

### **IS7, Practical considerations for CAR-T Cell Therapy use in lymphomas - Novartis Industry Symposium**

#### **Chairs:**

Anna Sureda (Spain)

**Introduction and opening remarks** 10:30 - 10:35  
Anna Sureda (Spain)

**CAR-T Cell Therapy in the DLBCL continuum of care: Efficacy and safety in key clinical trials and the real world** 10:35 - 10:55  
Matthew Frigault (United States)

**Patient selection for CAR-T Cell Therapy: What we know and what we have yet to find out** 10:55 - 11:10  
Anna Sureda (Spain)

**Treatment landscape in DLBCL: New developments, and when to take the CAR instead?** 11:10 - 11:30

**Interactive case-based panel session: How would you proceed?** 11:30 - 11:45  
Pere Barba (Spain)

## Scientific Programme

<b>Panel discussion and Q&amp;A</b>	<b>11:45 - 11:55</b>
<b>Closing remarks</b> Anna Sureda (Spain)	<b>11:55 - 12:00</b>

Industry Symposium  
10:30 - 12:00

Hall B (Exhibition Area)

### IS8, Maintenance of complete remission in AML - Celgene Industry Symposium

**Chairs:**

Hervé Dombret (France)

<b>Welcome and introduction</b> Hervé Dombret (France)	<b>10:30 - 10:40</b>
<b>Kinetics of clonal evolution and relapse in AML patients in complete response</b> Maria Teresa Voso (Italy)	<b>10:40 - 11:15</b>
<b>Current and upcoming pharmacological options to prolong complete response in AML</b> Charles Craddock (United Kingdom)	<b>11:15 - 11:50</b>
<b>Closing remarks</b> Hervé Dombret (France) Maria Teresa Voso (Italy) Charles Craddock (United Kingdom)	<b>11:50 - 12:00</b>

Industry Symposium  
10:30 - 12:00

Sala Retiro

### IS9, Case studies on innovative treatment approaches for CMV in HCT: A clinical forum - Takeda Industry Symposium

Nurses Group  
10:30 - 12:00

Sala Colón

### NG02, Nurses Education Day: Steroids - The haematology bad boys. Love them, loathe them, can't live without them

**Chairs:**

Caroline Bompont (France)  
Isabel Salcedo (Spain)

<b>Psychologic aspects: Compliance and survivorship</b> Sarah Dwinger (Germany)	<b>10:30 - 11:00</b>
<b>Avascular necrosis and osteoporosis</b> Nicola Chesman (United Kingdom)	<b>11:00 - 11:30</b>

## Scientific Programme

**Effects on immune system: Infections** **11:30 - 12:00**  
Lucrecia Yáñez San Segundo (Spain)

Lab Technicians Day  
10:30 - 12:00 N107

### LT1, Lab Technicians Day: Specialized cell processing

**Chairs:**

Harry Dolstra (Netherlands)

**Bone marrow processing: Techniques and results** **10:30 - 11:00**  
Boris Calmels (France)

**Technical aspects and performance TCRab depletion** **11:00 - 11:30**  
Kasper Westinga (Netherlands)

**Donor selection and GMP-compliant manufacturing of virus-specific T-cells** **11:30 - 12:00**  
Britta Eiz-Vesper (Germany)

Patient, Family Donor Day  
11:30 - 13:00 N101

### PFD2, Patient, Family and Donor Day: New developments

**Chairs:**

Guy Bouguet (France)

Bregje Verhoeven (Netherlands)

**Patient experience on CAR T** **11:30 - 11:40**

**Could CAR T-cell therapy save my life?** **11:40 - 12:10**  
Jürgen Kuball (Netherlands)

**HSCT for autoimmune disease and novel indications** **12:10 - 12:40**  
John Snowden (United Kingdom)

**Questions & Answers** **12:40 - 13:00**

Industry Symposium  
12:30 - 14:00 N103

### IS10, Jazz Pharmaceuticals Industry Symposium

## Scientific Programme

Industry Symposium  
12:30 - 14:00

Hall A (Exhibition Area)

### **IS11, Steroid-refractory GvHD: Current challenges and novel treatments on the horizon - Novartis Industry Symposium**

**Chairs:**

Franco Locatelli (Italy)

<b>Welcome and introduction</b>	<b>12:30 - 12:35</b>
Franco Locatelli (Italy)	
<b>GVHD and steroid-refractory GVHD in 2020</b>	<b>12:35 - 12:55</b>
Jeff Szer (Australia)	
<b>Today's challenges in managing acute and chronic steroid-refractory GVHD</b>	<b>12:55 - 13:05</b>
Franco Locatelli (Italy)	
<b>Panel discussion</b>	<b>13:05 - 13:10</b>
<b>Emerging therapies for steroid-refractory GVHD: Acute and chronic GVHD</b>	<b>13:10 - 13:40</b>
Madan Jagasia (United States) Robert Zeiser (Germany)	
<b>Panel discussion</b>	<b>13:40 - 13:55</b>
<b>Concluding remarks</b>	<b>13:55 - 14:00</b>
Franco Locatelli (Italy)	

Industry Symposium  
12:30 - 14:00

Hall B (Exhibition Area)

### **IS12, Current status and potential of CAR T-cell therapies in B-cell malignancies - Celgene Industry Symposium**

<b>Welcome and introduction</b>	<b>12:30 - 12:33</b>
<b>CAR T in DLBCL: The latest data and future perspectives</b>	<b>12:33 - 12:58</b>
<b>Beyond DLBCL: CAR T in high-risk or relapsing B-cell malignancies</b>	<b>12:58 - 13:23</b>
<b>The impact of CAR T on patient care organization</b>	<b>13:23 - 13:48</b>
<b>Discussion and Q&amp;A</b>	<b>13:48 - 13:58</b>
<b>Closing remarks</b>	<b>13:58 - 14:00</b>

Industry Symposium  
12:30 - 14:00

N105

### **IS13, Established and cutting-edge applications for cell therapies - Miltenyi Biotec Industry Symposium**

**Chairs:**

Rafael Duarte (Spain)

## Scientific Programme

<b>Welcome and introduction</b> Rafael Duarte (Spain)	<b>12:30 - 12:40</b>
<b>Picking your favorite tapas: Which cell populations to include in the allograft</b> Miguel-Angel Perales (United States)	<b>12:40 - 12:50</b>
<b>TCR<math>\alpha</math>/<math>\beta</math> CD19 depleted haploidentical HSCT in adult patients - Final results of the TCRalpha/beta-Haplo2010 study</b> Wolfgang Bethge (Germany)	<b>12:50 - 13:00</b>
<b>Improved survival rate in T cell-depleted haploidentical hematopoietic cell transplantation utilizing CD45RA-depleted grafts</b> Brandon Triplett (United States)	<b>13:00 - 13:10</b>
<b>Semi-automated CAR T cell manufacturing: focus on the UCL CAR T-cell programme</b> Claire Roddie (United Kingdom)	<b>13:10 - 13:20</b>

Industry Symposium  
12:30 - 14:00

Sala Retiro

### **IS14, Antineoplastic treatments and Invasive Mould Disease - Should we be worried and what can we do? - Pfizer Industry Symposium**

#### **Chairs:**

Samir Agrawal (United Kingdom)

<b>Introduction</b> Samir Agrawal (United Kingdom)	<b>12:30 - 12:35</b>
<b>An introduction to IMD in the haematology unit and epidemiology</b> Rafael de la Cámara (Spain)	<b>12:35 - 12:55</b>
<b>New therapies in haematology-oncology and the changing face of fungal disease</b> Samir Agrawal (United Kingdom)	<b>12:55 - 13:15</b>
<b>Choosing an invasive mould disease treatment in a complex environment</b> Federico Pea (Italy)	<b>13:15 - 13:35</b>
<b>A case study illustrating how to treat IMD and ensure continued treatment of the underlying condition</b> Amit Patel (United Kingdom)	<b>13:35 - 13:55</b>
<b>Discussion and closing</b>	<b>13:55 - 14:00</b>



## Scientific Programme

Nurses Group  
12:30 - 14:00

Sala Colón

### **NG03, Nurses Education Day: Steroids - The haematology bad boys. Love them, loathe them, can't live without them**

**Chairs:**

Caroline Bompont (France)  
Julia Ruiz (Spain)

<b>Steroids and sugar - Much ado about nothing?</b>	<b>12:30 - 13:00</b>
Matthias Hepprich (Switzerland)	
<b>Well-being on and off steroids: practical tips for nurses</b>	<b>13:00 - 13:30</b>
Diana Comerford (United Kingdom)	
<b>Patient testimony: weight gain, information, diabetes, relationships</b>	<b>13:30 - 14:00</b>
Agnès Huet-Vicens (France)	

Lab Technicians Day  
12:30 - 14:00

N107

### **LT2, Lab Technicians Day: Cell product testing, validation and characterization**

**Chairs:**

Britta Eiz-Vesper (Germany)

<b>Phenotyping and functional testing by flow cytometry</b>	<b>12:30 - 13:00</b>
Harry Dolstra (Netherlands)	
<b>Flow cytometry-based CD34 enumeration</b>	<b>13:00 - 13:30</b>
Harry Dolstra (Netherlands)	
<b>Flow cytometric in-process and quality control for CAR T-cell manufacturing</b>	<b>13:30 - 14:00</b>
Ulrike Köhl (Germany)	

Statistics  
13:00 - 16:00

N117

### **Stat2, Statistical Course: Survival Analysis**

<b>Survival Analysis</b>	<b>13:00 - 16:00</b>
Antonella Santucci (Italy) Richard Szydlo (United Kingdom)	

## Scientific Programme

Patient, Family Donor Day  
14:00 - 15:30

N101

### **PFD3, Patient, Family and Donor Day: Post-transplant care**

#### **Chairs:**

Lola Manterola (Spain)  
Isabel Salcedo (Spain)

<b>Patient experience on post-transplant</b>	<b>14:00 - 14:10</b>
Alfredo Arán (Spain)	
<b>A pathway for post-transplant care</b>	<b>14:10 - 14:30</b>
Fiona Dignan (United Kingdom)	
<b>Dealing with psychological effects</b>	<b>14:30 - 14:50</b>
Anna Barata (United States)	
<b>What about fertility?</b>	<b>14:50 - 15:05</b>
Mara Andrés Moreno (Spain)	
<b>The impact of stem cell transplants on sexuality, sexual functioning and sexual relationships</b>	<b>15:05 - 15:20</b>
Justin Grayer (United Kingdom)	
<b>Questions &amp; Answers</b>	<b>15:20 - 15:30</b>

Industry Symposium  
14:30 - 16:00

N103

### **IS15, Curative treatment intent in relapsed/refractory DLBCL: The role for CAR T-cell therapy - Gilead Industry Symposium**

Industry Symposium  
14:30 - 16:00

Hall A (Exhibition Area)

### **IS16, From kilometre zero - Navigating the myeloma treatment journey - Amgen Industry Symposium**

#### **Chairs:**

Mohamad Mohty (France)

<b>Introduction</b>	<b>14:30 - 14:40</b>
Mohamad Mohty (France)	
<b>Off to a good start - Optimal induction regimen for transplant eligible patients</b>	<b>14:40 - 15:05</b>
Francesca Gay (Italy)	
<b>The road beyond relapse - Therapeutic options for hard-to-treat patients</b>	<b>15:05 - 15:30</b>
Mohamad Mohty (France)	
<b>Panel discussion</b>	<b>15:30 - 16:00</b>

46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT),  
22 - 25 March 2020,  
Madrid, Spain

## Scientific Programme

Industry Symposium  
14:30 - 16:00

Hall B (Exhibition Area)

### **IS17, Targeted therapy for adult ALL: New horizons in the setting of alloHSCT - Amgen Industry Symposium**

**Chairs:**

Josep M. Ribera (Spain)

<b>Welcome and introduction</b>	<b>14:30 - 14:35</b>
Josep M. Ribera (Spain)	
<b>Overview of conventional approaches</b>	<b>14:35 - 14:45</b>
Josep M. Ribera (Spain)	
<b>Antibody-drug conjugates</b>	<b>14:45 - 15:05</b>
Matthias Stelljes (Germany)	
<b>T-cell engaging immunotherapy (BiTE® and CAR T)</b>	<b>15:05 - 15:35</b>
Nicola Gökbuget (Germany)	
<b>Panel discussion</b>	<b>15:35 - 15:55</b>
<b>Summary and meeting close</b>	<b>15:55 - 16:00</b>
Josep M. Ribera (Spain)	

Industry Symposium  
14:30 - 16:00

N105

### **IS18, The role of ECP in the treatment of GVHD - Mallinckrodt Industry Symposium**

**Chairs:**

Andrea Bacigalupo (Italy)

<b>Introduction</b>	<b>14:30 - 14:35</b>
Andrea Bacigalupo (Italy)	
<b>GVHD: Treatment goals and current definitions</b>	<b>14:35 - 15:00</b>
Madan Jagasia (United States)	
<b>ECP role in GVHD treatment</b>	<b>15:00 - 15:25</b>
Hildegard Greinix (Austria)	
<b>Combinatorial approaches in GVHD</b>	<b>15:25 - 15:50</b>
Robert Zeiser (Germany)	
<b>Q&amp;A</b>	<b>15:50 - 16:00</b>

## Scientific Programme

Industry Symposium  
14:30 - 16:00

Sala Retiro

### IS19, Targeted interventions in the natural history of Hodgkin Lymphoma - Takeda Industry Symposium

**Chairs:**

Anton Hagenbeek (Netherlands)

<b>Welcome and introduction</b> Anton Hagenbeek (Netherlands)	<b>14:30 - 14:40</b>
<b>Latest developments in frontline treatment of Hodgkin lymphoma</b> Martin Hutchings (Denmark)	<b>14:40 - 15:00</b>
<b>Panel discussion: Current trends and controversies in treatment of relapsed/refractory Hodgkin lymphoma with first salvage therapy</b> Anton Hagenbeek (Netherlands) Martin Hutchings (Denmark) Anna Sureda (Spain)	<b>15:00 - 15:30</b>
<b>Prolongation of remission with post-ASCT strategies in Hodgkin lymphoma</b> Anna Sureda (Spain)	<b>15:30 - 15:55</b>
<b>Closing</b> Anton Hagenbeek (Netherlands)	<b>15:55 - 16:00</b>

Industry Symposium  
14:30 - 16:00

Sala Colón

### IS20, Nurses' symposium: Power of knowledge: Nurses at the forefront of patient survival of severe hepatic VOD - Jazz Pharmaceuticals Industry Symposium

**Chairs:**

Michelle Kenyon (United Kingdom)

<b>Welcome and introduction</b> Michelle Kenyon (United Kingdom)	<b>14:30 - 14:35</b>
<b>Whose responsibility is it to identify patients with hepatic VOD?</b> Michelle Kenyon (United Kingdom)	<b>14:35 - 14:45</b>
<b>Nurses at the forefront of best practice</b> Caroline Bompont (France) Mairead Ni Chonghaile (Ireland)	<b>14:45 - 15:05</b>
<b>Knowledge is power: Paediatric hepatic VOD</b> Selim Corbacioglu (Germany) Zofia Szmit (Poland)	<b>15:05 - 15:30</b>
<b>The knowledge of the nurse: A case of severe hepatic VOD</b> Manos Nikolousis (United Kingdom)	<b>15:30 - 15:45</b>
<b>Q&amp;A</b>	<b>15:45 - 15:55</b>

## Scientific Programme

**Summary and closing** **15:55 - 16:00**  
Michelle Kenyon (United Kingdom)

Lab Technicians Day Industry Symposium **N107**  
14:30 - 16:00

### **IS21, Get moving with your CAR T-cell production - Establish your manufacturing with Miltenyi Biotec - Miltenyi Biotec Lab Technicians Workshop**

Patient, Family Donor Day **N101**  
16:00 - 16:45

### **PFD4, Patient, Family and Donor Day: Focus on the donor**

#### **Chairs:**

Lola Manterola (Spain)  
Julia Ruiz (Spain)

**Donor Registry: "A lifesaver". General and Spanish situation** **16:00 - 16:10**  
Enric Carreras (Spain)

**Donor and receiver from the pediatric point of view** **16:10 - 16:20**  
Antonio Pérez-Martínez (Spain)

**Donor - receiver: A child-focused testimony** **16:20 - 16:30**  
Daniel Guerrero (Spain)

**Questions & Answers** **16:30 - 16:45**

Industry Symposium **Hall B (Exhibition Area)**  
16:30 - 18:00

### **IS22, Cellular immune therapies for multiple myeloma - Celgene Industry Symposium**

#### **Chairs:**

María-Victoria Mateos Manteca (Spain)

**Welcome and introduction** **16:30 - 16:33**  
María-Victoria Mateos Manteca (Spain)

**State-of-the-art therapy in multiple myeloma and unmet needs in 2020** **16:33 - 16:58**  
María-Victoria Mateos Manteca (Spain)

**Overview of CAR T-cell treatment strategies in multiple myeloma** **16:58 - 17:23**  
Hermann Einsele (Germany)

**Management and optimization of CAR T-cell therapy** **17:23 - 17:48**  
Michel Delforge (Belgium)

**Discussion and Q&A** **17:48 - 17:58**

## Scientific Programme

**Closing remarks** **17:58 - 18:00**  
María-Victoria Mateos Manteca (Spain)

Industry Symposium  
16:30 - 18:00 N105

### **IS23, Management of CMV infections - MSD Industry Symposium**

Industry Symposium  
16:30 - 18:00 Sala Colón

### **IS24, Nurses' Symposium: From patient referral to long-term follow-up: The role of the specialist nurse in successful CAR T-cell therapy - Gilead Industry Symposium**

Special Session  
16:45 - 17:45 N101

### **SS1, The integration of patient voices in research in HSCT**

#### **Chairs:**

Hélène Schoemans (Belgium)  
Bregje Verhoeven (Netherlands)

**Patient's perspective** **16:45 - 16:57**  
Chris Lewis (United Kingdom)

**Physician's perspective** **16:57 - 17:09**  
Linda Burns (United States)

**Nurse's perspective** **17:09 - 17:21**  
Sarah Liptrott (Italy)

**Regulatory perspective** **17:21 - 17:33**  
Cristina Avendaño-Solá (Spain)

**Patient and public involvement: an essential strategy for effective implementation of innovative care models in stem cell transplantation** **17:33 - 17:45**  
Sabina De Geest (Switzerland)

Patient, Family Donor Day  
17:45 - 18:00 N101

### **PFD5, Patient, Family and Donor Day: Closing Remarks**

**Closing remarks** **17:45 - 17:55**  
Bregje Verhoeven (Netherlands)

**Welcome to Prague 2021** **17:55 - 18:00**  
Pavel Jindra (Czech Republic)

## Scientific Programme

General  
18:30 - 19:45

N103

### GS1, Opening Ceremony

#### Chairs:

Nicolaus Kröger (Germany)

Rafael Duarte (Spain)

John Murray (United Kingdom)

<b>Welcome and introduction</b> Nicolaus Kröger (Germany)	<b>18:30 - 18:40</b>
<b>Welcome and introduction to Madrid and the conference</b> Rafael Duarte (Spain)	<b>18:40 - 18:50</b>
<b>Welcome from the Nurses Group</b> John Murray (United Kingdom)	<b>18:50 - 18:55</b>
<b>EBMT Patient Advocacy Committee: Welcome note</b> Bregje Verhoeven (Netherlands)	<b>18:55 - 19:00</b>
<b>Honorary Member and Clinical Achievement Awards</b>	<b>19:00 - 19:20</b>
<b>Introduction of the Keynote speaker</b> Rafael Duarte (Spain)	<b>19:20 - 19:22</b>
<b>Keynote Lecture: How the treatment is evolving in transplant-eligible newly diagnosed Multiple Myeloma?</b> María-Victoria Mateos Manteca (Spain)	<b>19:22 - 19:45</b>

## Scientific Programme

### Monday, 23 March 2020

---

Meetings  
07:00 - 09:00 N101

#### **Cellular Therapy and Immunobiology Working Party Business Meeting**

Meetings  
07:00 - 09:00 N107

#### **Chronic Malignancies Working Party Business Meeting**

Meetings  
07:00 - 09:00 N109

#### **Severe Aplastic Anaemia Working Party Business Meeting**

Meetings  
07:00 - 09:00 N111

#### **Acute Leukemia Working Party Business Meeting**

Meetings  
07:00 - 09:00 N117

#### **Lymphoma Working Party Business Meeting**

Meetings  
07:00 - 09:00 N115

#### **Inborn Errors Working Party Business Meeting**

Meet the Expert  
08:00 - 09:00 Meet the Expert Rooms

#### **MTE-1, Meet the Expert session 1 - Room A10.01**

**Viral infections in HSCT recipients: The challenges in 2020** **08:00 - 09:00**  
Francisco Marty (United States)



## Scientific Programme

Meet the Expert  
08:00 - 09:00

Meet the Expert Rooms

### **MTE-2, Meet the Expert session 2 - Room A10.05**

**Extracorporeal photopheresis in the management of acute and chronic GVHD**

**08:00 - 09:00**

Daniel Couriel (United States)

Meet the Expert  
08:00 - 09:00

Meet the Expert Rooms

### **MTE-3, Meet the Expert session 3 - Room A10.06**

**The role of donor registries in the changing landscape of allogeneic HSCT in 2020**

**08:00 - 09:00**

Enric Carreras (Spain)

Meet the Expert  
08:00 - 09:00

Meet the Expert Rooms

### **MTE-4, Meet the Expert session 4 - Room A10.07**

**How to manage chronic GVHD in 2020 and beyond**

**08:00 - 09:00**

Steven Pavletic (United States)

Meet the Expert  
08:00 - 09:00

Meet the Expert Rooms

### **MTE-5, Meet the Expert session 5 - Room A10.12**

**The role of cord blood banks in the changing landscape of allogeneic HSCT in 2020**

**08:00 - 09:00**

Sergio Querol Giner (Spain)

Meet the Expert  
08:00 - 09:00

Meet the Expert Rooms

### **MTE-6, Meet the Expert session 6 - Room A10.13**

**How to establish a CAR T-cell Delivery Centre**

**08:00 - 09:00**

Claire Roddie (United Kingdom)

Meet the Expert  
08:00 - 09:00

Meet the Expert Rooms

### **MTE-7, Meet the Expert session 7 - Room A10.15**

## Scientific Programme

**How to manage acute promyelocytic leukemia in 2020. Current role of hematopoietic cell transplantation** 08:00 - 09:00  
Miguel Ángel Sanz Alonso (Spain)

Statistics  
08:30 - 10:30

EBMT 1 - Meeting Room

### Stat3, Statistical consulting

Psy Day  
08:45 - 10:30

N113

### Psy1, Workshop I: Survivorship programme

#### Chairs:

Frank Schulz-Kindermann (Germany)  
Alexandra Carpentier (Spain)

**Introduction** 08:45 - 09:00  
Anna Barata (United States)

**Survivorship** 09:00 - 09:45  
Karen Syrjala (United States)

**Working therapeutically with despair: Supporting patients with prolonged hospital admissions post-BMT** 09:45 - 10:30  
Surabhi Chaturvedi (United Kingdom)

Workshop  
09:00 - 10:30

N103

### W1, Unusual GVHD manifestations

#### Chairs:

Carmen Martínez Muñoz (Spain)  
Zinaida Peric (Croatia)

**Neurologic aspects of cGVHD** 09:00 - 09:30  
Ervina Bilic (Croatia)

**The kidney and GVHD - Is the kidney a target organ?** 09:30 - 10:00  
Sangeeta Hingorani (United States)

**Late acute GVHD and steroid refractory GVHD** 10:00 - 10:30  
Robert Zeiser (Germany)

## Scientific Programme

Educational  
09:00 - 10:30

Hall A (Exhibition Area)

### E1, Educational forum on microbiota and allogeneic HSCT

**Chairs:**

Ernst Holler (Germany)  
Sergio Giralt (United States)

<b>Current understanding of the impact of microbiome on HSCT alloreactive phenomena and outcome</b>	<b>09:00 - 09:30</b>
Daniela Weber (Germany)	
<b>Gut microbiota and GVHD in children</b>	<b>09:30 - 10:00</b>
Riccardo Masetti (Italy)	
<b>Preventive and therapeutic interventions in the microbiota</b>	<b>10:00 - 10:30</b>
Florent Malard (France)	

Nurses Group  
09:00 - 10:30

Hall B (Exhibition Area)

### NG04, Nurses Programme Opening Session

**Chairs:**

John Murray (United Kingdom)  
Julia Ruiz (Spain)

<b>Welcome and overview</b>	<b>09:00 - 09:10</b>
John Murray (United Kingdom)	
<b>Presentation of the 12th Distinguished Merit Award</b>	<b>09:10 - 09:20</b>
John Murray (United Kingdom)	
<b>Extensive role of nurses</b>	<b>09:20 - 09:50</b>
<b>Keynote lecture: Artificial Intelligence in health care</b>	<b>09:50 - 10:30</b>
Shahrukh Hashmi (United States)	

Workshop  
09:00 - 10:30

N105

### W2, Controversies in T-cell NHL

**Chairs:**

Dolores Caballero (Spain)  
Luca Castagna (France)

<b>Are we improving first-line therapy in TCL?</b>	<b>09:00 - 09:25</b>
Eva Domingo Domènech (Spain)	
<b>Is HSCT the way forward for PTCL?</b>	<b>09:25 - 09:50</b>
Norbert Schmitz (Germany)	

## Scientific Programme

<b>Insights in CAR T therapy for T-cell lymphomas</b> Karl Peggs (United Kingdom)	<b>09:50 - 10:15</b>
<b>Round table discussion</b>	<b>10:15 - 10:30</b>

Cell therapy  
09:00 - 10:30

N101

### CTD1, Cell Therapy Day: Large-scale access to marketed CAR T-Cells

#### Chairs:

Olaf Penack (Germany)  
Manel Juan (Spain)

<b>Collecting autologous MNC for industry manufactured CAR T-cells: When and how</b> Elad Jacoby (Israel)	<b>09:00 - 09:30</b>
<b>Addressing bottlenecks in CAR T-cell manufacturing</b> Ulrike Köhl (Germany)	<b>09:30 - 10:00</b>
<b>Management of OOS CAR T-cell products</b> Alexey Bersenev (United States)	<b>10:00 - 10:30</b>

Oral Session  
09:00 - 10:30

Sala Retiro

### OS1, Oral session

Working Party Session  
09:00 - 10:30

Sala Colón

### IDWP, Infectious Diseases Working Party Session

#### Chairs:

Jan Styczynski (Poland)  
Malgorzata Mikulska (Italy)

<b>IDWP activity 2019-2020 and highlights of ECIL</b> Jan Styczynski (Poland)	<b>09:00 - 09:05</b>
<b>Current scientific proposals of IDWP</b> Malgorzata Mikulska (Italy)	<b>09:05 - 09:10</b>
<b>Infections after CAR T therapy</b> Lidia Gil (Poland) Dina Averbuch (Israel)	<b>09:10 - 09:25</b>
<b>Highlights of ECIL: Recommendations in community-acquired respiratory virus infections</b> Hans Hirsch (Switzerland)	<b>09:25 - 09:45</b>

## Scientific Programme

<b>Highlights of ECIL: Recommendations in invasive fungal disease in children</b> Andreas Groll (Germany)	<b>09:45 - 10:05</b>
<b>Highlights of ECIL: Recommendations in pediatric febrile neutropenia</b> Thomas Lehrnbecher (Germany)	<b>10:05 - 10:25</b>
<b>Summary and Conclusions</b> Jan Styczynski (Poland)	<b>10:25 - 10:30</b>

Working Party Session  
09:00 - 10:30

N107

### CMWP, Chronic Malignancies Working Party Session

#### Chairs:

Donal McLornan (United Kingdom)  
Stéphanie Nguyen Quoc (France)

<b>Welcome and introduction</b> Patrick Hayden (Ireland)	<b>09:00 - 09:10</b>
<b>Allogeneic hematopoietic cell transplantation in aggressive mastocytosis</b> Gandhi Damaj (France)	<b>09:10 - 09:40</b>
<b>Round table: implication of Artificial Intelligence in HC transplantation and cellular therapy approaches</b> Alsuliman Tamim (France) Ramana Reddy (United States) Layth Sliman (France)	<b>09:40 - 10:30</b>

Working Party Session  
09:00 - 10:30

N109

### ADWP, Autoimmune Diseases Working Party Session

#### Chairs:

John Snowden (United Kingdom)  
Tobias Alexander (Germany)

<b>Introduction</b> John Snowden (United Kingdom)	<b>09:00 - 09:05</b>
<b>Autologous HSCT in MS: Will delivery early in the disease course improve outcomes? How can we work with the neurological community to select the most appropriate patients?</b> Giovanni Mancardi (Italy)	<b>09:05 - 09:20</b>
<b>Questions</b>	<b>09:20 - 09:25</b>
<b>Autologous HSCT in SSc: Will delivery early in the disease course improve outcomes? What disease markers should we use to select patients?</b> Jacob M. van Laar (Netherlands)	<b>09:25 - 09:40</b>
<b>Questions</b>	<b>09:40 - 09:45</b>

## Scientific Programme

<b>Autologous HSCT in Crohn's disease: Will delivery early in the disease course improve outcomes? What disease markers should we use to select patients?</b>	<b>09:45 - 10:00</b>
Elena Ricart (Spain)	
<b>Questions</b>	<b>10:00 - 10:05</b>
<b>HSCT in Immune Cytopenias: Is there still a role alongside modern management strategies? How should we select patients?</b>	<b>10:05 - 10:20</b>
Nichola Cooper (United Kingdom)	
<b>Questions</b>	<b>10:20 - 10:25</b>
<b>Close and summary</b>	<b>10:25 - 10:30</b>
Tobias Alexander (Germany)	

Oral Session  
09:00 - 10:30

N111

### OS2, Oral session

Transplant Coordinator Day  
09:00 - 10:30

Sala Neptuno

### TCD1, EBMT-WMDA Transplant Coordinators Day: New HLA Typing Techniques and how they changed the way to transplant

**Chairs:**

Machteld Oudshoorn (Netherlands)  
Joannis Mytilineos (Germany)

<b>Introduction and Overview</b>	<b>09:00 - 09:20</b>
Machteld Oudshoorn (Netherlands)	
<b>Debate: Do we still need Verification Typing (VT) of the donor?</b>	
<b>No, rely on initial high resolution typing</b>	<b>09:20 - 09:45</b>
Matthias Stelljes (Germany)	
<b>Yes, safety first</b>	<b>09:45 - 10:10</b>
Rachel Pawson (United Kingdom)	
<b>Panel discussion</b>	<b>10:10 - 10:30</b>

Data Management  
09:00 - 10:30

N117

### DM1, Education session 1

**Chairs:**

Lucas Stolarczyk (United Kingdom)

## Scientific Programme

### Discussion forum - Cell therapy

Chiara Bonini (Italy)  
Jürgen Kuball (Netherlands)  
Álvaro Urbano-Ispizua (Spain)  
Lawrence Vermeir (United Kingdom)

09:00 - 10:30

Data Management  
09:00 - 10:30

N118

### DM13, Training session 1 (pre-registration required)

#### MACRO data entry

Asterios Kasmiris (United Kingdom)

09:00 - 10:30

Joint Session  
09:00 - 10:30

N115

### JS1, Joint session ASTCT/CIBMTR: Bridging the gap in BMT and cellular therapy between North America and Europe

#### Chairs:

Navneet Majhail (United States)  
Robert Soiffer (United States)  
Nicolaus Kröger (Germany)

#### A tale of two continents: Differences and similarities in BMT practices in North America and Europe

Robert Soiffer (United States)

09:00 - 09:30

#### Landscape of CAR T-cell therapy in North America and Europe: Lessons learned and future directions

Miguel-Angel Perales (United States)

09:30 - 10:00

#### Looking back and moving forward: Blueprint for collaborative international studies in BMT and Cellular therapy

Anna Sureda (Spain)

10:00 - 10:30

Industrial Theatre  
10:30 - 11:00

Industry Theatre

### IT1, Sanofi Genzyme Industry Theatre Session

## Scientific Programme

Plenary Session  
11:00 - 12:30

N103

### P1, Gene Therapy for Inherited Disorders in 2020

**Chairs:**

Cristina Díaz de Heredia (Spain)  
Arjan Lankester (Netherlands)

<b>Gene therapy in Fanconi Anemia</b>	<b>11:00 - 11:22</b>
Juan Bueren (Spain)	
<b>Gene therapy in leucodystrophies and other metabolic disorders</b>	<b>11:22 - 11:44</b>
Maria Ester Bernardo (Italy)	
<b>Hemoglobinopathies</b>	<b>11:44 - 12:06</b>
Selim Corbacioglu (Germany)	
<b>The future of gene therapy for primary immunodeficiencies</b>	<b>12:06 - 12:28</b>
Claire Booth (United Kingdom)	

Educational  
11:00 - 12:30

Hall A (Exhibition Area)

### E2, Waldenström Macroglobulinemia

**Chairs:**

Silvia Montoto (United Kingdom)  
Maria José Terol Castera (Spain)

<b>How biology in Waldenström Macroglobulinemia may affect treatment strategy?</b>	<b>11:00 - 11:30</b>
Véronique Leblond (France)	
<b>Conventional and new drugs</b>	<b>11:30 - 12:00</b>
Ramón García-Sanz (Spain)	
<b>Hematopoietic stem cell transplantation in Waldenström Macroglobulinemia</b>	<b>12:00 - 12:30</b>
Charalampia Kyriakou (United Kingdom)	

Workshop  
11:00 - 12:30

Hall B (Exhibition Area)

### W3, Steroid-refractory chronic GVHD

**Chairs:**

Hildegard Greinix (Austria)  
Carlos Solano Vercet (Spain)

<b>Pulmonary steroid-refractory chronic GVHD</b>	<b>11:00 - 11:30</b>
Hildegard Greinix (Austria)	
<b>Ocular cGVHD diagnostics - How to properly diagnose ocular cGVHD?</b>	<b>11:30 - 12:00</b>
Igor Petricek (Croatia)	



## Scientific Programme

**Gastrointestinal manifestations of chronic GVHD** 12:00 - 12:30  
Daniel Wolff (Germany)

Educational  
11:00 - 12:30

N105

### E3, Emerging and personalized approaches in MDS

#### Chairs:

Juan Carlos Hernández-Boluda (Spain)  
Christoph Scheid (Germany)

**Microtransplantation** 11:00 - 11:30  
Micha Srouf (France)

**Emerging and personalized cellular therapy approaches for myeloid diseases** 11:30 - 12:00  
Marco Davila (United States)

**Risk assessment of patients with CMML** 12:00 - 12:30  
Francesco Onida (Italy)

Cell therapy  
11:00 - 12:30

N101

### CTD2, Cell Therapy Day: Biotechnological developments

#### Chairs:

Annalisa Ruggeri (France)  
Lotte Wieten (Netherlands)

**Evolving technologies for gene modification / gene editing of hematopoietic stem cells and immune effector cells** 11:00 - 11:30  
Chiara Bonini (Italy)

**Where are we with mesenchymal stem cells in 2020?** 11:30 - 12:00  
Francesco Dazzi (United Kingdom)

**Hematopoietic stem cell expansion: latest preclinical and clinical results** 12:00 - 12:30  
Elizabeth Shpall (United States)

Oral Session  
11:00 - 12:30

Sala Retiro

### OS3, Oral session

## Scientific Programme

Working Party Session  
11:00 - 12:30

Sala Colón

### TCWP, Transplant Complications Working Party Session

**Chairs:**

Grzegorz Basak (Poland)  
Zinaida Peric (Croatia)

<b>Introduction</b>	<b>11:00 - 11:05</b>
Grzegorz Basak (Poland)	
<b>Fecal microbiota transplantation for GVHD</b>	<b>11:05 - 11:17</b>
Jaroslav Bilinski (Poland)	
<b>Evaluation of VOD scoring</b>	<b>11:17 - 11:29</b>
Tapani Ruutu (Finland)	
<b>EASIX index as a prognostic tool</b>	<b>11:29 - 11:41</b>
Olaf Penack (Germany)	
<b>Male-specific late effects: An update on a joint EBMT/CIBMTR systematic review</b>	<b>11:41 - 11:53</b>
Rachel Phelan (United States)	
<b>Importance of patient-reported outcomes - survey</b>	<b>11:53 - 12:05</b>
Hélène Schoemans (Belgium)	
<b>Steroid-refractory GVHD - survey</b>	<b>12:05 - 12:17</b>
Zinaida Peric (Croatia)	
<b>EBMT GVHD recommendations</b>	<b>12:17 - 12:29</b>
Olaf Penack (Germany)	

Meetings  
11:00 - 11:40

N107

### Nurses Group Annual Business Meeting

**Chairs:**

Daphna Hutt (Israel)

Transplant Coordinator Day  
11:00 - 12:30

Sala Neptuno

### TCD2, EBMT-WMDA Transplant Coordinators Day: Donor attrition and backup strategies

**Chairs:**

Annette Rasche (Germany)  
Maria Teresa Solano Moliner (Spain)

<b>Ethics of donation and donor attrition at the search stage</b>	<b>11:00 - 11:30</b>
Bernice Elger (Switzerland)	

## Scientific Programme

**Donor-related cancellations at the final (work-up) stage** 11:30 - 12:00  
Katalin Balassa (United Kingdom)

**Back-up strategy along graft request** 12:00 - 12:30  
Irina Evseeva (United Kingdom)

Psy Day  
11:00 - 12:30

N113

### Psy2, Workshop II: Donors, caregivers and the transplant team

**Chairs:**

Alice Polomeni (France)  
Soledad de Linares Fernández (Spain)

**The dynamics of donor commitment** 11:00 - 11:30  
Suzanna M. van Walraven (Netherlands)

**Supporting transplant caregivers** 11:30 - 12:00  
Maria Die Trill (Spain)

**Supporting the transplant team** 12:00 - 12:30  
Alice Polomeni (France)

Data Management  
11:00 - 11:40

N117

### DM2, Education session 2

**Chairs:**

Helen Baldomero (Switzerland)

**Registry upgrade and other data collection news in the EBMT** 11:00 - 11:40  
Per Ljungman (Sweden)

Data Management  
11:00 - 12:30

N118

### DM14, Training session 1 (continued) (pre-registration required)

**MACRO data entry** 11:00 - 12:30  
Asterios Kasmiris (United Kingdom)

## Scientific Programme

Joint Session  
11:00 - 12:30

N115

### JS2, Joint session EHA: Moving CAR T-Cell Therapy in Europe

#### Chairs:

John Gribben (United Kingdom)  
Nicolaus Kröger (Germany)

<b>Academic CAR T-cell development in Europe</b>	<b>11:00 - 11:30</b>
Álvaro Urbano-Ispizua (Spain)	
<b>Center Qualification Process in Europe</b>	<b>11:30 - 12:00</b>
Jorge Sierra (Spain)	
<b>Sharing CAR T-cell data: Governance structure of EBMT Cellular Therapy registry</b>	<b>12:00 - 12:30</b>
Jürgen Kuball (Netherlands)	

How do I ... ?  
11:00 - 12:30

A9.13

### HDI1, How Do I... mobilize autologous stem cells - Supported through an unrestricted educational grant by Sanofi Genzyme

#### Chairs:

Carmen Martínez Chamorro (Spain)  
Adrián Alegre (Spain)

<b>After antibody and ImiDS based induction in MM patients</b>	<b>11:00 - 11:30</b>
Francesca Gay (Italy)	
<b>If tandem transplant is planned in myeloma</b>	<b>11:30 - 12:00</b>
Patrick Wuchter (Germany)	
<b>By optimizing apheresis centre time</b>	<b>12:00 - 12:30</b>
José Luis Bueno (Spain)	

Special Session  
11:15 - 12:30

Industry Theatre

### SS2, Social media session - Do's and don'ts of the interaction in the social media for the HSCT and cell therapy community

#### Chairs:

Pere Barba (Spain)  
Miguel-Angel Perales (United States)

<b>Social media beyond Twitter for the HSCT and Cell Therapy community</b>	<b>11:15 - 11:35</b>
Navneet Majhail (United States)	
<b>Do's and don'ts of interaction in social media: nurse's perspective</b>	<b>11:35 - 11:55</b>
Diana Comerford (United Kingdom)	

## Scientific Programme

**Do's and don'ts of interaction in social media: patient's perspective** 11:55 - 12:15  
Gillian Adams (United Kingdom)

**Panel discussion** 12:15 - 12:30

Nurses Group  
11:40 - 12:30

N107

### NG05, Cellular Therapy update

#### Chairs:

Esperanza Santos (Spain)  
Letizia Galgano (Italy)

**What's new?** 11:40 - 12:05  
Órla Stewart (United Kingdom)

**Guidelines** 12:05 - 12:30  
Rose Ellard (United Kingdom)

Nurses Group  
11:40 - 12:30

N109

### NG06, How do I manage... Protective isolation?

#### Chairs:

Birgit Keinrath (Austria)  
Yolanda Guijarro Herraiz (Spain)

**The case for** 11:40 - 12:05  
Iris Agreiter (Ireland)

**The case against** 12:05 - 12:30  
Cristina Gallego (Spain)

Nurses Group  
11:40 - 12:30

N111

### NG07, Patients and donors preparation

#### Chairs:

Mairead Ni Chonghaile (Ireland)  
Rodrigo Serrano (Spain)

**Patient work-up** 11:40 - 12:05  
Manuela Salinero (Spain)

**Donor work-up** 12:05 - 12:30  
Annika Kisch (Sweden)

## Scientific Programme

Data Management  
11:50 - 12:30

N117

### DM3, Education session 3

**Chairs:**

Julia Lee (United Kingdom)

**Molecular diagnostic markers: Interpreting the results of molecular diagnostics for Med-A/B forms**

**11:50 - 12:30**

April Sellors (United Kingdom)

Industry Symposium  
13:00 - 14:15

N103

### IS25, Your decisions in action: The reality of severe hepatic VOD management - Jazz Pharmaceuticals Industry Symposium

**Chairs:**

Mohamad Mohty (France)

**Welcome and introduction**

**13:00 - 13:05**

Mohamad Mohty (France)

**Informed decision-making for paediatric hepatic VOD**

**13:05 - 13:20**

Selim Corbacioglu (Germany)

**The patient: Your important initial choices in action**

**13:20 - 13:35**

Rafael Duarte (Spain)

**Assessment and monitoring, what now?**

**13:35 - 13:50**

Antonio Pagliuca (United Kingdom)

**Outcome: The reality of severe hepatic VOD**

**13:50 - 14:05**

Mohamad Mohty (France)

**Q&A**

**14:05 - 14:13**

**Summary and closing**

**14:13 - 14:15**

Mohamad Mohty (France)

Industry Symposium  
13:00 - 14:00

Hall A (Exhibition Area)

### IS26, An update on induction and front-line therapy for transplantation-eligible patients with MM - Janssen Industry Symposium

**Chairs:**

María-Victoria Mateos Manteca (Spain)

**Introduction**

**13:00 - 13:02**

María-Victoria Mateos Manteca (Spain)

## Scientific Programme

<b>Latest data on treatment approaches for transplant eligible patients in frontline MM</b>	<b>13:02 - 13:22</b>
Philippe Moreau (France)	
<b>Panel discussion</b>	<b>13:22 - 13:30</b>
María-Victoria Mateos Manteca (Spain)	
Philippe Moreau (France)	
Niels van de Donk (Netherlands)	
<b>How will recent data change your clinical practice? - Clinical case studies focusing on patients with 'standard' and 'high' risk MM</b>	<b>13:30 - 14:00</b>
María-Victoria Mateos Manteca (Spain)	
Niels van de Donk (Netherlands)	

CME Symposium  
13:00 - 14:00

Hall B (Exhibition Area)

### IS27, Gene Therapy - CME Symposium

Industry Symposium  
13:00 - 14:00

N105

### IS28, Nurses' symposium: Therakos ECP Immunomodulation - How and why - Mallinckrodt Industry Symposium

#### Chairs:

John Murray (United Kingdom)

<b>Welcome and introduction</b>	<b>13:00 - 13:05</b>
John Murray (United Kingdom)	
<b>The role of nurses in delivering ECP - Special patient conditions</b>	<b>13:05 - 13:20</b>
Britt Storm (Denmark)	
<b>ECP: evaluation of cell collection efficiency</b>	<b>13:20 - 13:40</b>
Nina Worel (Austria)	
<b>My GVHD and ECP journey - A patient story</b>	<b>13:40 - 13:55</b>
Wilfred Emmanuel-Jones (United Kingdom)	
<b>Q&amp;A</b>	<b>13:55 - 14:00</b>

Statistics  
13:00 - 14:30

N115

### Stat4, Statistics symposium

#### Chairs:

Liesbeth de Wreede (Netherlands)  
Hein Putter (Netherlands)

## Scientific Programme

<b>Sensitivity Analysis: E-value based on directly adjusted survival probabilities</b> Mei-jie Zhang (United States)	<b>13:00 - 13:30</b>
<b>Methods for missing data in competing risks</b> Édouard Bonneville (Netherlands)	<b>13:30 - 14:00</b>
<b>Bayesian methods for early detection of treatment effects in phase 3 trials with survival endpoints</b> Lucie Biard (France)	<b>14:00 - 14:30</b>

Industrial Theatre  
13:00 - 13:30

Industry Theatre

### IT2, Medac Industry Theatre Session

Industry Symposium  
13:00 - 14:00

Meet the Expert Rooms

### IS29, Celgene Industry Meet the Expert Lunch - Room A10.05

<b>Management of cellular therapies in RRMM</b> Albert Oriol (Spain)	<b>13:00 - 14:00</b>
---	----------------------

Industry Symposium  
13:00 - 14:00

Meet the Expert Rooms

### IS30, Takeda Industry Meet the Expert Lunch - Room A10.06

<b>Treatment paradigm in higher-risk MDS</b> Guillermo Sanz Santillana (Spain)	<b>13:00 - 14:00</b>
---	----------------------

Industrial Theatre  
13:45 - 14:15

Industry Theatre

### IT3, Gilead Industry Theatre Session

General  
14:30 - 16:00

N103

### GS2, Presidential Symposium

**Chairs:**  
Nicolaus Kröger (Germany)  
Rafael Duarte (Spain)



## Scientific Programme

Cell therapy  
14:30 - 16:00

N101

### **CTD3, Cell Therapy Day: Conditions for implementation of innovative hematopoietic cellular therapies**

#### **Chairs:**

Jürgen Kuball (Netherlands)  
Éliane Gluckman (France)

<b>Ethics beyond gene editing</b>	<b>14:30 - 15:00</b>
Aurélie Mahalatchimy (France)	
<b>Access to Gene Therapies in Tanzania</b>	<b>15:00 - 15:30</b>
Julie Makani (Tanzania, United Republic of)	
<b>Integration of care and research leading to individualized treatment</b>	<b>15:30 - 16:00</b>
Miriam Koopman (Netherlands)	

Nurses Group  
14:30 - 16:00

N107

### **NG08, Oral Session 1: Best paediatric abstracts**

#### **Chairs:**

Hilda Mekelenkamp (Netherlands)  
Carmen Conde (Spain)

<b>TRANSITION STRATEGY: FROM PEDIATRIC TO ADULT HEALTH CARE AND LONG TERM FOLLOW-UP</b>	<b>14:30 - 14:48</b>
<u>Julia Ruiz Pato</u> , Marta Ausín Fernández, Ana Aida Casado Pardo, Rebeca García Heras, Laura Lozano Ferreiro, Pilar Herreros López, Miguel Ángel Díaz Perez (Spain)	
<b>CAREGIVER EDUCATION AND TRAINING FOR SELF ADMINISTRATION OF ORAL DRUGS IN A PAEDIATRIC CENTER</b>	<b>14:48 - 15:06</b>
<u>Giuseppe Marco Deiana</u> , Evelina Olcese, Simona Calza, Paolo Petralia, Silvia Scelsi (Italy)	
<b>EXERCISE THERAPY ON CANCER-RELATED FATIGUE AND QUALITY OF LIFE IN CHILDREN UNDERGOING UMBILICAL CORD BLOOD TRANSPLANTATION</b>	<b>15:06 - 15:24</b>
<u>Lu Huang</u> , Chengzhen Jia, Yun Wu (China)	
<b>SEXUAL HEALTH FOR YOUNG PEOPLE UNDERGOING HAEMATOPOIETIC STEM CELL TRANSPLANTATION</b>	<b>15:24 - 15:42</b>
<u>Lisa Burnett</u> , Kayleigh Douglas (United Kingdom)	
<b>NURSES´ VIEW ON COMBINING TWO DIFFERENT SPECIALTIES; HEMATOLOGY-ONCOLOGY, HSCT AND ORGAN TRANSPLANTS</b>	<b>15:42 - 16:00</b>

## Scientific Programme

Nurses Group  
14:30 - 16:00

N109

### NG09, How do I... understand blood counts?

#### Chairs:

Montserrat Barrilero López (Spain)

<b>Liver counts</b>	<b>14:30 - 14:50</b>
Ignacio Alberto Gómez Centurión (Spain)	
<b>Renal counts</b>	<b>14:50 - 15:10</b>
Iván López-Torija (Spain)	
<b>Full blood counts</b>	<b>15:10 - 15:35</b>
Maria Esther Martínez Muñoz (Spain)	
<b>Cross matching</b>	<b>15:35 - 16:00</b>
Josune Zubicaray Salegui (Spain)	

Nurses Group  
14:30 - 16:00

N111

### NG10, Supportive and palliative care

#### Chairs:

Sandra Schoenfeld (Switzerland)

Lowes Alonso Llobregat (Spain)

<b>Meaning centered care</b>	<b>14:30 - 15:00</b>
Katharina Scheffold (Germany)	
<b>Challenges in decision-making: End of life</b>	<b>15:00 - 15:30</b>
Jakob Passweg (Switzerland)	
<b>Early integration and parallel planning</b>	<b>15:30 - 16:00</b>
Richard Towers (United Kingdom)	

Transplant Coordinator Day  
14:30 - 16:00

Sala Neptuno

### TCD3, EBMT-WMDA Transplant Coordinators Day: Training for Transplant Coordinators - A Workshop to find out your needs (at the Meet the Expert rooms)

<b>Round table: Interactive discussions and exchange - Rooms A10.12, A10.13, A10.15</b>	<b>14:30 - 16:00</b>
Irina Evseeva (United Kingdom)	
Annette Rasche (Germany)	
Suzanna M. van Walraven (Netherlands)	

## Scientific Programme

Psy Day  
14:30 - 16:00 N113

### Psy3, How do I...?

**Chairs:**

Karen Syrjala (United States)  
Maria Die Trill (Spain)

**How do I... Evaluate psychosocial factors and complexities that may influence the HSCT process and outcomes?** 14:30 - 15:00

Alex King (United Kingdom)

**How do I... Address the psycho-oncologists well-being?** 15:00 - 15:30

Frank Schulz-Kindermann (Germany)

**How do I... Identify unmet needs and plan research?** 15:30 - 16:00

Corinna Bergelt (Germany)

Data Management  
14:30 - 15:10 N117

### DM4, Education session 4

**Chairs:**

Linda Koster (Netherlands)

**Response in Multiple Myeloma** 14:30 - 15:10

Meral Beksac (Turkey)

Data Management  
14:30 - 16:00 N118

### DM15, Training session 2 (pre-registration required)

**MACRO Reports** 14:30 - 16:00

Silvia Zaccagnino (United Kingdom)

How do I ... ?  
14:30 - 16:00 A9.13

### HDI2, How Do I... consider patients' needs in induction and front line therapy for transplant (eligible patients with Multiple Myeloma) - Nurses Session - Supported through an unrestricted educational grant by Janssen

**Chairs:**

Maaïke de Ruijter (Netherlands)

**Treatment approaches for transplant eligible patients in front line Multiple Myeloma** 14:30 - 15:00

Laure Vincent (France)

## Scientific Programme

**How do new therapy combinations offer newly diagnosed Multiple Myeloma patients benefits, case studies** 15:00 - 15:30  
Sarah Henshaw (United Kingdom)

**How do I.....consider patient's needs from a psycho-social perspective?** 15:30 - 16:00  
Surabhi Chaturvedi (United Kingdom)

Data Management  
15:20 - 16:00

N117

### DM5, Education Session 5

**Chairs:**

Beate Lindner (Austria)

**Follow up forms - How to get a chronological overview of the patient history and follow up** 15:20 - 16:00  
Elena Ferrer Martínez (Spain)

Industrial Theatre  
16:00 - 16:30

Industry Theatre

### IT4, KYMRIA in the Real World - Novartis Industry Theatre Session

Industry Symposium  
16:30 - 18:00

N103

### IS31, Antibody Therapy in Acute Leukemia: Understanding Clinical Considerations for Use in Conjunction with HSCT - Pfizer Industry Symposium

**Chairs:**

David I. Marks (United Kingdom)

**Welcome and introduction** 16:30 - 16:35  
David I. Marks (United Kingdom)

**MasterClass 1: Understanding the transplant context in AML and considerations with antibody therapy** 16:35 - 17:00  
Farhad Ravandi (United States)

**MasterClass 2: Insights on the integration of novel antibodies as options for transplant-eligible patients with ALL** 17:00 - 17:25  
David I. Marks (United Kingdom)

**Practicum: A case-based exploration of antibody therapy in AML/ALL transplant recipients** 17:25 - 17:50  
David I. Marks (United Kingdom)  
Farhad Ravandi (United States)  
Matthias Stelljes (Germany)

**Symposium summary, reflection, and audience Q&A** 17:50 - 18:00  
David I. Marks (United Kingdom)

## Scientific Programme

Industry Symposium  
16:30 - 18:00

Hall A (Exhibition Area)

### IS32, HSCT-TMA - Omeros Industry Symposium

Oral Session  
16:30 - 18:00

Hall B (Exhibition Area)

### OS4, Oral session

Educational  
16:30 - 18:00

N105

### E4, What's new in the pathophysiology and treatment of patient complications?

#### Chairs:

Eolia Brissot (France)  
Gustavo Kusminsky (Argentina)

<b>CAR T toxicity</b>	<b>16:30 - 16:52</b>
Julio Delgado (Spain)	
<b>Early transplant complications</b>	<b>16:52 - 17:14</b>
Christian Koenecke (Germany)	
<b>Acute GVHD</b>	<b>17:14 - 17:36</b>
Olaf Penack (Germany)	
<b>Pathophysiology and treatment of chronic GVHD</b>	<b>17:36 - 17:58</b>
José Antonio Pérez-Simón (Spain)	

Cell therapy  
16:30 - 18:00

N101

### CTD4, Cell Therapy Day: Modern developments in immunogenetics and immunology in the context of HSCT

#### Chairs:

Luca Vago (Italy)  
Katharina Fleischhauer (Germany)

<b>Immunogenetics in the era of NGS and haplo-mismatched transplantations</b>	<b>16:30 - 17:00</b>
Valérie Dubois (France)	
<b>Immunogenetics of hematopoietic stem cell transplantation</b>	<b>17:00 - 17:30</b>
Effie Petersdorf (United States)	
<b>Immune monitoring of patients treated with immune effector cells</b>	<b>17:30 - 18:00</b>
Raffaella Greco (Italy)	

## Scientific Programme

Workshop  
16:30 - 18:00

Sala Retiro

### **W4, When modern hematology and anti-infective drugs meet at CYP450**

#### **Chairs:**

Oliver Cornely (Germany)  
Juan Diego Vélez (Colombia)

<b>Is it time TDM our recent hematologic advances?</b>	<b>16:30 - 16:52</b>
Roger Brüggemann (Netherlands)	
<b>Crossroads of life-saving drugs - A clinical perspective in modern hematology?</b>	<b>16:52 - 17:14</b>
Jannik Stemler (Germany)	
<b>Practical consequences of co-administration of life-saving drugs</b>	<b>17:14 - 17:36</b>
<b>A regulatory perspective on evaluating TDM and DDI with current anti-infective standards in hematology drug development</b>	<b>17:36 - 17:58</b>
Arantxa Sancho (Spain)	

Industry Symposium  
16:30 - 18:00

Sala Colón

### **HDI3, How do I... Expect, predict and improve survival of severe hepatic VOD? - Supported by Jazz Pharmaceuticals**

<b>Welcome and introduction</b>	<b>16:30 - 16:35</b>
<b>Expect severe hepatic VOD</b>	<b>16:35 - 16:45</b>
Antonio Colecchia (Italy)	
<b>Ultrasound and Doppler in action (live demonstration)</b>	<b>16:45 - 17:10</b>
Nathalie Lassau (France)	
<b>Predict severe hepatic VOD</b>	<b>17:10 - 17:30</b>
Antonio Pagliuca (United Kingdom) Thomas Luft (Germany)	
<b>Improve survival of severe hepatic VOD</b>	<b>17:30 - 17:45</b>
Antonio Pagliuca (United Kingdom)	
<b>Q&amp;A</b>	<b>17:45 - 17:55</b>
<b>Summary and closing</b>	<b>17:55 - 18:00</b>

Nurses Group  
16:30 - 18:00

N107

### **NG11, Oral Session 2: Abstract finalists**

#### **Chairs:**

Caroline Bompont (France)  
Janet Baker (United Kingdom)

## Scientific Programme

<b>FAMILY CAREGIVERS SUPPORT NEEDS DURING ALLO-HSCT - A LONGITUDINAL STUDY (PRELIMINARY RESULTS)</b>	<b>16:30 - 16:48</b>
<i>Annika M Kisch, Karin Bergkvist, Anette Alvariza, Jeanette Winterling (Sweden)</i>	
<b>PAIN AND ANXIETY MANAGEMENT DURING BONE MARROW ASPIRATES IN ITALIAN TRANSPLANT PROGRAMS. A NATIONWIDE SURVEY ON BEHALF OF GITMO NG</b>	<b>16:48 - 17:06</b>
<b>ROLE OF QUICKSOFA IN PREDICTING SEPSIS AND SEPTIC SHOCK IN HEMATOLOGICAL PATIENTS</b>	<b>17:06 - 17:24</b>
<i>Anna Carmagnola, Alessia Arioli, Giulia Righi, Francesca Vergara, Massimo Bernardi, Consuelo Corti, Fabio Giglio, Daniela Clerici, Jacopo Peccatori, Raffaella Greco, Fabio Ciceri, Antonella Biella (Italy)</i>	
<b>&lt;i&gt;BOLUS:&lt;/i&gt; TARGETED SPECIALIST HAEMATOLOGY/BMT PODCASTS: AN EFFECTIVE METHOD OF EDUCATION</b>	<b>17:24 - 17:42</b>
<b>A PATHWAY FOR RECOVERY: D+100 AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANT (AHSCT) FOLLOW UP PILOT FOR LYMPHOMA</b>	<b>17:42 - 18:00</b>

Nurses Group  
16:30 - 18:00

N109

### NG12, Care of the nurses

#### Chairs:

Marie Waller (United Kingdom)  
Cristina Canaletta Ros (Spain)

<b>Mindfulness</b>	<b>16:30 - 17:00</b>
<i>Troy Chase (United Kingdom)</i>	
<b>Leadership</b>	<b>17:00 - 17:30</b>
<i>Klara Kabatova Maxova (Czech Republic)</i>	
<b>Tips and tricks for self care</b>	<b>17:30 - 18:00</b>
<i>Jane Keep (United Kingdom)</i>	

Nurses Group  
16:30 - 18:00

N111

### NG13, Non-malignant diseases update

#### Chairs:

Seckin Erdal (Turkey)  
Ariadna Domènech (Spain)

<b>Aplastic anemia</b>	<b>16:30 - 16:55</b>
<i>Simon Slade (United Kingdom)</i>	
<b>Sickle cell disease</b>	<b>16:55 - 17:15</b>
<i>Jean-Hugues Dalle (France)</i>	
<b>Multiple sclerosis</b>	<b>17:15 - 17:35</b>
<i>Helen Jessop (United Kingdom)</i>	

## Scientific Programme

**ITP** **17:35 - 18:00**  
Elena Sebastián (Spain)

Transplant Coordinator Day Sala Neptuno  
16:30 - 18:00

### **TCD4, EBMT-WMDA Transplant Coordinators Day: Family donations**

**Chairs:**

Suzanna M. van Walraven (Netherlands)  
Nina Worel (Austria)

**Children as donors - Psychological aspects** **16:30 - 17:00**  
Galen Switzer (United States)

**International Family Donation - How Registries can help** **17:00 - 17:30**  
Ann O'Leary (United Kingdom)

**Follow up on related donors - The Swiss solution** **17:30 - 18:00**  
Grazia Nicoloso (Switzerland)

Psy Day N113  
16:30 - 18:00

### **Psy4, Abstract session**

**Chairs:**

Angela Scherwath (Germany)  
Anna Barata (United States)

Data Management N117  
16:30 - 17:10

### **DM6, Education session 6**

**Chairs:**

Emmanuelle Polge (France)

**Treatment of relapse after transplant (DLI, CAR T, second allograft)** **16:30 - 17:10**  
Nicolaus Kröger (Germany)

Data Management N118  
16:30 - 17:30

### **DM16, Training session 2 (continued) (pre-registration required)**

**MACRO Reports** **16:30 - 17:30**  
Silvia Zaccagnino (United Kingdom)



## Scientific Programme

Oral Session  
16:30 - 18:00

N115

### OS5, Oral session

Joint Session  
16:30 - 18:00

A9.13

### JS3, Joint session WBMT: International access to HCT drugs: Impact on transplant practice and patients

#### Chairs:

Daniel Weisdorf (United States)  
Carlos Solano Vercet (Spain)

<b>Causes of drug shortages and finding enduring solutions</b>	<b>16:30 - 17:00</b>
<b>How can pharmacists help the HCT team in drug shortages and cost of medications</b> Gunar Stemer (Austria)	<b>17:00 - 17:30</b>
<b>Successful models of cooperation to offer essential drugs in the care of HCT patients: role of WBMT</b> Hildegard Greinix (Austria)	<b>17:30 - 18:00</b>

## Scientific Programme

### Tuesday, 24 March 2020

---

Meetings  
07:00 - 09:00 N101

#### **Paediatric Diseases Working Party Business Meeting**

Meetings  
07:00 - 09:00 N109

#### **Autoimmune Diseases Working Party Business Meeting**

Meetings  
07:00 - 09:00 N111

#### **Infectious Diseases Working Party Business Meeting**

Meetings  
07:00 - 09:00 N113

#### **Transplant Complications Working Party Business Meeting**

Quality Management  
08:00 - 09:00 Sala Colón

#### **QM1, Introduction to JACIE**

**Chairs:**  
Esther Zafra (Spain)

**Accreditation process** 08:00 - 08:15

Eva Controle (Spain)

**Basic quality management concepts** 08:15 - 08:30

Ivana Ferrero (Italy)

**Lessons learned from first-time inspections and re-accreditation inspections** 08:30 - 08:45

Carole Charley (United Kingdom)

**Questions & Answers** 08:45 - 09:00

## Scientific Programme

Meet the Expert  
08:00 - 09:00

Meet the Expert Rooms

### **MTE-8, Meet the Expert Session 8 - Room A10.01**

**HSCT in high-risk MDS**  
David Valcárcel Ferreiras (Spain)

**08:00 - 09:00**

Meet the Expert  
08:00 - 09:00

Meet the Expert Rooms

### **MTE-9, Meet the Expert Session 9 - Room A10.05**

**Prophylaxis of acute graft versus host disease: ATG or not ATG?**  
Francesca Bonifazi (Italy)

**08:00 - 09:00**

Meet the Expert  
08:00 - 09:00

Meet the Expert Rooms

### **MTE-10, Meet the Expert Session 10 - Room A10.06**

**Clinical hurdles for academic development of clinical Advanced Therapies: the perspective from the GMP Lab**  
Felipe Prosper (Spain)

**08:00 - 09:00**

Meet the Expert  
08:00 - 09:00

Meet the Expert Rooms

### **MTE-11, Meet the Expert Session 11 - Room A10.07**

**The fast changing paradigm of myeloma treatment: What's best in 2020?**  
Sergio Giralt (United States)

**08:00 - 09:00**

Meet the Expert  
08:00 - 09:00

Meet the Expert Rooms

### **MTE-12, Meet the Expert Session 12 - Room A10.12**

**How I manage double hit lymphomas**  
Andrew Davies (United Kingdom)

**08:00 - 09:00**

Meet the Expert  
08:00 - 09:00

Meet the Expert Rooms

### **MTE-13, Meet the Expert Session 13 - Room A10.13**

## Scientific Programme

**The role of HSCT in mantle cell lymphoma in 2020** **08:00 - 09:00**  
Olivier Hermine (France)

Meet the Expert  
08:00 - 09:00

Meet the Expert Rooms

### MTE-14, Meet the Expert Session 14 - Room A10.15

**Maintenance strategies after allogeneic HSCT in patients with AML** **08:00 - 09:00**  
Ali Bazarbachi (Lebanon)

Multi-stakeholder Forum on Innovative Cellular Therapies  
08:30 - 09:30

Sala Retiro

### MF1, 1st Multi-stakeholder Forum on Innovative Cellular Therapies: Introduction and welcome

#### Chairs:

Christian Chabannon (France)  
Harry Dolstra (Netherlands)

**Introduction and welcome** **08:30 - 08:45**  
Christian Chabannon (France)

**Keynote Lecture: EMA's Regulatory Science to 2025 in the area HSCT and gene/cellular therapies** **08:45 - 09:30**  
Jordi Llinares (Netherlands)

Statistics  
08:30 - 10:30

EBMT 1 - Meeting Room

### Stat5, Statistical consulting

Plenary Session  
09:00 - 10:30

N103

### P2, Artificial Intelligence approaching Hemato-oncology and HSCT

#### Chairs:

Rafael Duarte (Spain)  
Nicolaus Kröger (Germany)

**Basic concepts, applications, and limitations of Machine Learning: A primer for hematologists** **09:00 - 09:22**  
Roni Shouval (United States)

**Artificial Intelligence in hematology** **09:22 - 09:44**  
Grzegorz Basak (Poland)

## Scientific Programme

<b>Artificial Intelligence to support clinical decision making on infections in hematology</b> Carolina García-Vidal (Spain)	<b>09:44 - 10:06</b>
<b>The role of technology and Artificial Intelligence in GVHD</b> Shahrukh Hashmi (United States)	<b>10:06 - 10:28</b>

Educational  
09:00 - 10:30

Hall A (Exhibition Area)

### E5, Long-term management of alloHSCT recipients

#### Chairs:

María del Mar Perera Álvarez (Spain)  
Patrice Chevallier (France)

<b>Survivorship care plans</b> Navneet Majhail (United States)	<b>09:00 - 09:22</b>
<b>Secondary malignancies</b> Christian Koenecke (Germany)	<b>09:22 - 09:44</b>
<b>Endocrine complications</b> Diana Greenfield (United Kingdom)	<b>09:44 - 10:06</b>
<b>Practical management of long-term organ complications</b> Mutlu Arat (Turkey)	<b>10:06 - 10:28</b>

Oral Session  
09:00 - 10:30

Hall B (Exhibition Area)

### OS6, Oral session

Educational  
09:00 - 10:30

N105

### E6, Infectious complications: new therapies and prevention

#### Chairs:

Jan Styczynski (Poland)  
Rafael de la Cámara (Spain)

<b>Multiresistant bacteria in children and adults: insight on new antibiotics</b> Dina Averbuch (Israel)	<b>09:00 - 09:30</b>
<b>Management strategies in the new adenovirus landscape</b> Per Ljungman (Sweden)	<b>09:30 - 10:00</b>
<b>How to structure an effective HSCT vaccine program</b> Catherine Cordonnier (France)	<b>10:00 - 10:30</b>

## Scientific Programme

Paediatric Day  
09:00 - 10:30

N101

### Paediatrics1, Paediatric Diseases Working Party Session

#### Chairs:

Selim Corbacioglu (Germany)  
Persis Amrolia (United Kingdom)

#### **PDWP update on prospective activities**

#### **PDWP activities and next events**

Selim Corbacioglu (Germany)

**09:00 - 09:10**

#### **Cell based therapies in children**

#### **Overview of novel developments in CAR T**

Hinrich Abken (Germany)

**09:10 - 09:20**

#### **CD5- and CD7-directed CAR T Cells for T-cell malignancies**

Maksim Mamonkin (United States)

**09:20 - 09:30**

#### **Adoptive transfer of multivirus-specific T-cells**

Tobias Feuchtinger (Germany)

**09:30 - 09:40**

#### **Real world Data: relapse after CAR T**

Susana Rives (Spain)

**09:40 - 09:50**

#### **"Real World Data" on CAR T: HSCT vs. CAR T in leukemia**

Peter Bader (Germany)

**09:50 - 10:00**

#### **Beyond Europe**

#### **Brazil**

Carmem Bonfim (Brazil)

**10:00 - 10:15**

#### **Mexico**

Alberto Olaya-Vargas (Mexico)

**10:15 - 10:30**

Quality Management  
09:00 - 10:30

Sala Colón

### QM2, Draft 8th Edition of the STD

#### Chairs:

Eugenia Trigo Arjona (Spain)

#### **Clinical standards**

Kim Orchard (United Kingdom)

**09:00 - 09:15**

#### **Collections standards**

Nina Worel (Austria)

**09:15 - 09:30**

#### **Processing standards**

Ivan van Riet (Belgium)

**09:30 - 09:45**

#### **Quality Management standards**

Simon Hack (United Kingdom)

**09:45 - 10:00**

## Scientific Programme

<b>Immune effector cells standards</b> Riccardo Saccardi (Italy)	<b>10:00 - 10:15</b>
<b>Questions &amp; Answers</b>	<b>10:15 - 10:30</b>

Nurses Group  
09:00 - 10:30

N107

### NG14, Joint session: Teamwork in the CAR T-cells setting

#### Chairs:

Maaïke de Ruijter (Netherlands)  
Sara Marcos Corrales (Spain)

<b>Indications and patient selection</b> Reuben Benjamin (United Kingdom)	<b>09:00 - 09:30</b>
<b>Training the UK workforce</b> Ian Hollingsworth (United Kingdom)	<b>09:30 - 10:00</b>
<b>Quality of life in caregivers and patients undergoing CAR T therapy</b> Anna Barata (United States)	<b>10:00 - 10:30</b>

Special Session  
09:00 - 10:30

N109

### SS3, Young Ambassadors session

#### Chairs:

Razan Mohty (France)  
Abdul Hamid Bazarbachi (United States)

#### How to build up a career in:

<b>Academia</b> Didier Blaise (France)	<b>09:00 - 09:10</b>
<b>Pharmaceutical Industry</b> Suzanne Janssen (France)	<b>09:10 - 09:20</b>
<b>Public domains</b> Eva Hilgenfeld (Germany)	<b>09:20 - 09:30</b>
<b>What to avoid when writing a paper</b> Jakob Passweg (Switzerland)	<b>09:30 - 09:45</b>
<b>How to write a successful grant</b> Robert Zeiser (Germany)	<b>09:45 - 10:00</b>
<b>Introduction to medical statistics</b> Simona Iacobelli (Italy)	<b>10:00 - 10:15</b>
<b>Social media in stem cell transplantation and cellular therapy</b> Navneet Majhail (United States)	<b>10:15 - 10:30</b>

## Scientific Programme

Workshop  
09:00 - 10:30

N111

### W5, Bone marrow failure: From diagnosis to treatment in 2020

#### Chairs:

Carlos Vallejo (Spain)  
Andrea Bacigalupo (Italy)

<b>Constitutional BMF diagnosis work-up in the era of NGS and gene panels</b>	<b>09:00 - 09:30</b>
Carlo Dufour (Italy)	
<b>Guidelines for the use of eltrombopag in aplastic anemia in Europe</b>	<b>09:30 - 10:00</b>
Régis Peffault de Latour (France)	
<b>New complement inhibitors: Time for the show</b>	<b>10:00 - 10:30</b>
Antonio Risitano (Italy)	

Workshop  
09:00 - 10:30

Sala Neptuno

### W6, Donor HLA assessment and matching for allogeneic HSCT

#### Chairs:

Katharina Fleischhauer (Germany)  
Alejandro Madrigal (United Kingdom)

<b>HLA laboratory perspective and recommendations</b>	<b>09:00 - 09:30</b>
<b>Clinical perspective and recommendations</b>	<b>09:30 - 10:00</b>
Francesca Lorentino (Italy)	
<b>Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: Guidelines from NMDP/CIBMTR</b>	<b>10:00 - 10:30</b>
Stephen Spellman (United States)	

Pharmacists Day  
09:00 - 10:30

N113

### Pharm1, Pharmacotherapy in HSCT

#### Chairs:

Rick Admiraal (Netherlands)  
Maria Estela Moreno Martínez (Spain)

<b>General introduction: Local Pharmacy Committee and EBMT Pharmacists Committee</b>	<b>09:00 - 09:10</b>
Tiene Bauters (Belgium) Maria Estela Moreno Martínez (Spain)	
<b>Current evidence for TDM in HSCT: An overview</b>	<b>09:10 - 09:30</b>
Vera Domingos (Portugal)	
<b>GFR estimation in HSCT patients: Is creatinine enough?</b>	<b>09:30 - 09:50</b>
Claudia Langebrake (Germany)	



## Scientific Programme

<b>Drug-Drug Interactions between antifungals and immunosuppressive agents: An EBMT guidance</b>	<b>09:50 - 10:10</b>
Erik van Maarseveen (Netherlands)	
<b>ATG vs. post-cyclophosphamide</b>	<b>10:10 - 10:30</b>
Eolia Brissot (France)	

Data Management  
09:00 - 10:30 N117

### DM7, Education session 7

**Chairs:**

Helen Baldomero (Switzerland)

<b>Discussion forum - Med A</b>	<b>09:00 - 10:30</b>
Helen Baldomero (Switzerland)	
Hildegard Greinix (Austria)	
Lidia Gil (Poland)	
Johannes Schetelig (Germany)	
Sebastian Giebel (Poland)	

Data Management  
09:00 - 10:30 N118

### DM17, Training session 1 (pre-registration required)

<b>MACRO Data Entry</b>	<b>09:00 - 10:30</b>
Asterios Kasmiris (United Kingdom)	

Special Session  
09:00 - 10:30 N115

### SS4, Gender Equality forum

**Chairs:**

Silvia Montoto (United Kingdom)

Anna Sureda (Spain)

John Murray (United Kingdom)

<b>Physician's (female) perspective</b>	<b>09:00 - 09:22</b>
Jane Apperley (United Kingdom)	
<b>Physician's (male) perspective</b>	<b>09:22 - 09:44</b>
John Snowden (United Kingdom)	
<b>Nurse's perspective</b>	<b>09:44 - 10:06</b>
John Murray (United Kingdom)	
<b>The role of gender in doctor-patient interaction and outcomes</b>	<b>10:06 - 10:28</b>
Natacha Bolaños (Spain)	

## Scientific Programme

How do I ... ?  
09:00 - 10:30

A9.13

### **HDI4, How Do I... manufacture T-cells for cellular therapies - Supported through an unrestricted educational grant by Miltenyi Biotec**

#### **Chairs:**

João Lacerda (Portugal)

<b>Home-brew CAR T-Cells</b>	<b>09:00 - 09:30</b>
Michael Schmitt (Germany)	
<b>Generating antiviral T-cells for clinical application</b>	<b>09:30 - 10:00</b>
Britta Eiz-Vesper (Germany)	
<b>Generation of T regulatory cells</b>	<b>10:00 - 10:30</b>
Mauro Di Ianni (Italy)	

Special Session  
09:00 - 10:00

Industry Theatre

### **SS5, How to get published**

<b>BMT: Official journal of the EBMT</b>	<b>09:00 - 09:20</b>
Hillard Lazarus (United States)	
<b>How to get published</b>	<b>09:20 - 09:40</b>
Mohamad Mohty (France)	
<b>Questions &amp; Answers</b>	<b>09:40 - 10:00</b>

Multi-stakeholder Forum on Innovative Cellular Therapies  
09:30 - 10:30

Sala Retiro

### **MF2, Multi-stakeholder Forum on Innovative Cellular Therapies: The regulatory framework for new therapies for Dummies**

#### **Chairs:**

Mark Lowdell (United Kingdom)  
Christian Chabannon (France)

<b>The development of new ATMPs from an academic perspective: Hurdles and opportunities</b>	<b>09:30 - 09:50</b>
Pauline Meij (Netherlands)	
<b>National view</b>	<b>09:50 - 10:10</b>
Blanca García-Ochoa (Spain)	
<b>Real-world regulatory issues in the implementation of Advanced Therapies</b>	<b>10:10 - 10:30</b>
Encarnación Cruz Martos (Spain)	

## Scientific Programme

Plenary Session  
11:00 - 12:30

N103

### P3, Patient Reported Outcomes - A new paradigm in HSCT

#### Chairs:

Rafael Duarte (Spain)  
Hélène Schoemans (Belgium)  
Guy Bouguet (France)

<b>Do PRO predict HSCT outcome?</b> Bronwen Shaw (United States)	<b>11:00 - 11:22</b>
<b>Optimizing the management of GVHD using patient reported outcome measures</b> Rubeta Matin (United Kingdom)	<b>11:22 - 11:44</b>
<b>Patient-Reported Outcomes in CAR T-cell therapy</b> Anna Barata (United States)	<b>11:44 - 12:06</b>
<b>Integrating the patient in HSCT research projects</b> Linda Burns (United States)	<b>12:06 - 12:28</b>

Workshop  
11:00 - 12:30

Hall A (Exhibition Area)

### W7, CARs beyond T-cells: A focus on next generation CAR-NK cells

#### Chairs:

Joaquín Martínez-López (Spain)  
Katy Rezvani (United States)

<b>CAR NK cells as an "off the shelf" immunotherapy</b> Ulrike Köhl (Germany)	<b>11:00 - 11:30</b>
<b>CAR-NK cells against hematological malignancies</b> Katy Rezvani (United States)	<b>11:30 - 12:00</b>
<b>Atypical CAR-NKG2D cells - natural receptor/ligand to target tumors</b> Antonio Pérez-Martínez (Spain)	<b>12:00 - 12:30</b>

Workshop  
11:00 - 12:30

Hall B (Exhibition Area)

### W8, Controversies in patients with DLBCL

#### Chairs:

Anna Sureda (Spain)

<b>Anything better than R-CHOP for first-line therapy?</b> Umberto Vitolo (Italy)	<b>11:00 - 11:25</b>
<b>Has HSCT come to an end in relapsed disease?</b>	<b>11:25 - 11:50</b>

## Scientific Programme

<b>CAR T-cells in relapsed/refractory DLBCL and beyond</b> Alberto Mussetti (Spain)	<b>11:50 - 12:15</b>
<b>Round table discussion</b>	<b>12:15 - 12:30</b>

Working Party Session  
11:00 - 12:30

N105

### **ALWP, Acute Leukemia Working Party Session - Moving away from traditional immunosuppression in acute leukemia**

**Chairs:**

Mohamad Mohty (France)  
Sebastian Giebel (Poland)

<b>Welcome and introduction</b> Mohamad Mohty (France)	<b>11:00 - 11:15</b>
<b>Biological mechanisms of GVHD prevention with PTCy</b> Leo Luznik (United States)	<b>11:15 - 11:40</b>
<b>PT-Cy vs. ATG in 9/10 MUD transplant for acute myeloid leukemia</b> Giorgia Battipaglia (France)	<b>11:40 - 11:55</b>
<b>PT-Cy vs. ATG in acute lymphoblastic leukemia</b> Arnon Nagler (Israel)	<b>11:55 - 12:10</b>
<b>PT-Cy and ATG combination for high risk AML</b> Mohamad Mohty (France)	<b>12:10 - 12:25</b>
<b>Round table discussion</b>	<b>12:25 - 12:30</b>

Paediatric Day  
11:00 - 12:30

N101

### **Paediatrics2, Inborn Errors Working Party Session**

**Chairs:**

Arjan Lankester (Netherlands)  
Michael Albert (Germany)

<b>Landscape of GT and allogeneic Therapy in IEM: The next years</b> Robert Wynn (United Kingdom)	<b>11:00 - 11:15</b>
<b>Therapeutic standards for patients with SCID- still a matter of discussion</b> Manfred Hoenig (Germany)	<b>11:15 - 11:30</b>
<b>Antibody based conditioning</b> Agnieszka Czechowicz (United States)	<b>11:30 - 11:45</b>
<b>Bridging to transplant in combined immunodeficiencies: role of clinical scores and targeted treatments</b> Markus Seidel (Austria)	<b>11:45 - 12:00</b>

## Scientific Programme

<b>Inflammation and autoimmunity in PID: Does it matter for HSCT?</b>	<b>12:00 - 12:15</b>
Bénédicte Neven (France)	
<b>Discussion</b>	<b>12:15 - 12:30</b>

Multi-stakeholder Forum on Innovative Cellular Therapies  
11:00 - 12:00

Sala Retiro

### **MF3, Multi-stakeholder Forum on Innovative Cellular Therapies: Outcome data capture - challenges and opportunities**

**Chairs:**

Nicolaus Kröger (Germany)  
Jorge Gayoso (Spain)

<b>EMA Patient Registry initiative</b>	<b>11:00 - 11:20</b>
<b>EBMT Clinical Trials Office: Cell Therapy data capture</b>	<b>11:20 - 11:40</b>
Marianne Mol (Netherlands)	
<b>Industry</b>	<b>11:40 - 12:00</b>

Quality Management  
11:00 - 12:00

Sala Colón

### **QM3, Inspectors Session**

**Chairs:**

Carolina Herranz (Spain)

<b>JACIE Activity Report &amp; update</b>	<b>11:00 - 11:10</b>
Raquel Espada (Spain)	
<b>Most frequent non-compliances from the 7th Edition of the STD</b>	<b>11:10 - 11:30</b>
Louise McNamara (United Kingdom)	
<b>Inspection team: Roles</b>	<b>11:30 - 11:50</b>
Mara Magri (Italy) Nick van Sinderen (Netherlands)	
<b>Questions &amp; Answers</b>	<b>11:50 - 12:00</b>

Nurses Group  
11:00 - 12:30

N107

### **NG15, Disease update**

**Chairs:**

Marijke Quaghebeur (Belgium)  
Patricia Moreno Galán (Spain)

<b>Acute leukemia</b>	<b>11:00 - 11:20</b>
Elisabeth Wallhult (Sweden)	

## Scientific Programme

<b>Managing lymphoma: What nurses and healthcare Professionals need to know</b> Erik Aerts (Switzerland)	<b>11:20 - 11:40</b>
<b>Multiple Myeloma</b> Maaïke de Ruijter (Netherlands)	<b>11:40 - 12:05</b>
<b>Myeloproliferative disorders / CML (TKI management)</b> Irene Caballes (United Kingdom)	<b>12:05 - 12:30</b>

Nurses Group  
11:00 - 12:30

N109

### NG16, Paediatric Session

#### Chairs:

Teija Schröder (Finland)

<b>Impact of a health information technology tool addressing information needs of caregivers of adult and pediatric hematopoietic stem cell transplantation patients</b> Alex Fauer (United States)	<b>11:00 - 11:30</b>
<b>Music therapy supported quality of life and coping strategies for children during and after hematopoietic stem cell transplant</b> Lena Uggla (Sweden)	<b>11:30 - 12:00</b>
<b>Gamified mobile health intervention triumph to prevent psychological problems and support behavior change: Learnings from a qualitative study among pediatric cancer patients</b> Kadri Haljas (Estonia)	<b>12:00 - 12:30</b>

Nurses Group  
11:00 - 12:30

N111

### NG17, Research Committee Session: Oral Session 3 - Research Abstract finalists

#### Chairs:

Sarah Liptrott (Italy)  
Isabel Salcedo (Spain)

<b>SOCIAL SUPPORT MODERATES THE EFFECTS OF HEALTH STRESSORS ON HEALTH CARE ADHERENCE AND PSYCHOLOGICAL DISTRESS IN LONG-TERM HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) SURVIVORS</b> <u>Kristina Nørskov</u> , Jean C. Yi, Marie-Laure Crouch, Karen L. Syrjala (Denmark)	<b>11:00 - 11:18</b>
<b>THE EFFECT OF RELAXING BREATHING EXERCISES ON PAIN, FATIGUE AND LEUKOCYTE COUNT IN ADULT PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION</b> <u>Esra Bayrak</u> , Gulbeyaz Can (Turkey)	<b>11:18 - 11:36</b>

## Scientific Programme

**SYMPTOMS AND QUALITY OF LIFE OF CHILDREN AND ADOLESCENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION OR CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY** 11:36 - 11:54

Jessica Ward, Paula Murray, Kimberly Powers, Jilayne Smith, Melody Hellsten (United States)

**STUDY ON COGNITIVE FUNCTION AND RELATED FACTORS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION** 11:54 - 12:12

Yun Fang, Xiaorong Zhang, Minjie Liu, Weiwei Zhang (China)

**SYMPTOM DISTRESS DURING THE FIRST YEAR AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION - A PROSPECTIVE STUDY** 12:12 - 12:30

Workshop  
11:00 - 12:30

Sala Neptuno

### W9, Autoimmune diseases

#### Chairs:

Tobias Alexander (Germany)  
Montserrat Rovira (Spain)

**HSCT in AD - Inducing tolerance through autologous and allogeneic HSCT** 11:00 - 11:30  
Raffaella Greco (Italy)

**HSCT in AD - 20 years of evolution to evidence-based specialty guidelines** 11:30 - 12:00  
John Snowden (United Kingdom)

**HSCT in AD - The Latin American perspective in 2020** 12:00 - 12:30  
Maria Carolina Oliveira Rodrigues (Brazil)

Pharmacists Day  
11:00 - 12:30

N113

### Pharm2, Management of adverse events

#### Chairs:

Tiene Bauters (Belgium)  
Vera Pires (Portugal)

**Management of adverse events of CAR T (tisagenlecleucel) in paediatrics** 11:00 - 11:20  
Barbara de Moerloose (Belgium)

**CAR T and the clinical pharmacist - Standardisation of toxicity management across the UK** 11:20 - 11:40  
Sumantha Gabriel (United Kingdom)  
Jackie Chappell (United Kingdom)

**Management of mucositis in HSCT** 11:40 - 12:00  
Filipa Cosme Silva (Portugal)

**Chemotherapy Induced Nausea and Vomiting** 12:00 - 12:20  
Sumantha Gabriel (United Kingdom)

**Discussion** 12:20 - 12:30

## Scientific Programme

Data Management  
11:00 - 11:40

N117

### DM8, Education session 8

**Chairs:**

Mohamed Houhou (France)

**Minimal residual disease (MRD)**

**11:00 - 11:40**

Johannes Schetelig (Germany)

Data Management  
11:00 - 12:30

N118

### DM18, Training session 1 (continued) (pre-registration required)

**MACRO Data Entry**

**11:00 - 12:30**

Asterios Kasmiris (United Kingdom)

Oral Session  
11:00 - 12:30

N115

### OS7, Oral session

How do I ... ?  
11:00 - 12:30

A9.13

### HDI5, How Do I... reduce therapeutic toxicity in GVHD therapy - Supported through an unrestricted educational grant by Mallinckrodt

**Chairs:**

Daniel Wolff (Germany)

**Strategies to avoid CNI as GVHD prophylaxis**

**11:00 - 11:45**

Olaf Penack (Germany)

**Cell based option to treat GVHD**

**11:45 - 12:30**

Hildegard Greinix (Austria)

Data Management  
11:50 - 12:30

N117

### DM9, Education session 9

**Chairs:**

Nina Knelange (Netherlands)

**Infectious complications**

**11:50 - 12:30**

Malgorzata Mikulska (Italy)



## Scientific Programme

Multi-stakeholder Forum on Innovative Cellular Therapies  
12:00 - 13:00

Sala Retiro

### **MF4, Multi-stakeholder Forum on Innovative Cellular Therapies: Health Technology Assessment**

#### **Chairs:**

Eoin McGrath (Spain)  
Beatriz Domínguez-Gil (Spain)

<b>The US view</b>	<b>12:00 - 12:20</b>
Miguel-Angel Perales (United States)	
<b>An EU view</b>	<b>12:20 - 12:40</b>
Giovanni Tafuri (Netherlands)	
<b>A national view</b>	<b>12:40 - 13:00</b>
Amr Makady (Netherlands)	

Quality Management  
12:00 - 12:30

Sala Colón

### **QM4, Role of Quality Management Professionals in Stem Cell Transplant Programs**

#### **Chairs:**

Julia Ruiz (Spain)

<b>Results of the survey QM role</b>	<b>12:00 - 12:20</b>
Renza Monteleone (Italy)	
<b>Questions &amp; Answers</b>	<b>12:20 - 12:30</b>

Industrial Theatre  
12:45 - 13:30

Industry Theatre

### **IT5, MSD Industry Theatre Session**

Quality Management  
13:00 - 14:00

Sala Colón

### **QM5, QM Meet the Expert Sessions - located at the Meet the Expert rooms (topic pre-registration is required)**

<b>QM Meet the Expert Sessions</b>	<b>13:00 - 14:00</b>
<b>QM MTE 1: Risk &amp; Change Management - Room A10.05</b>	
Dieter Klarmann (Germany) Olga López Villar (Spain)	
<b>QM MTE 2: Audits &amp; Document development and control - Room A10.06</b>	
Renza Monteleone (Italy) Julie Dolva (Norway)	

## Scientific Programme

### **QM MTE 3: Adverse events & CAPA - Room A10.07**

Anne Emmett (United Kingdom)

### **QM MTE 4: Maintaining the QM program and QM plan - Room A10.12**

Nick van Sinderen (Netherlands)  
Phuong Huynh (Belgium)

### **QM MTE 5: Outcome analysis and benchmarking & Validation and verification - Room A10.13**

Mara Magri (Italy)  
Kim Orchard (United Kingdom)

### **QM MTE 6: Personnel, Training and Competency - Room A10.15**

Ilknur Kozanoglu (Turkey)  
Songül Tepebasi (Turkey)

Statistics  
13:00 - 13:45

Sala Neptuno

## **Stat6, Statistics Workshop**

### **Chairs:**

Myriam Labopin (France)  
Xavier Poiré (Belgium)

### **Different method to analyse time-dependent covariates: The example of GVL**

**13:00 - 13:45**

Ariane Boumendil (France)  
Avichai Shimoni (Israel)

Industry Symposium  
13:00 - 14:00

Meet the Expert Rooms

## **IS33, Mallinckrodt Industry Meet the Expert Lunch - Room A10.01**

### **Calibrating the intensity of GVHD therapy to allow clinical tolerance - A role for ECP?**

**13:00 - 14:00**

Daniel Wolff (Germany)

Industry Symposium  
13:00 - 14:00

Meet the Expert Rooms

## **IS34, Medac Industry Meet the Expert Lunch - Room EBMT 3**

## Scientific Programme

Pharmacists Day  
13:30 - 14:00

N113

### Pharm3, Abstract Session

**Chairs:**

Erik van Maarseveen (Netherlands)

Industrial Theatre  
13:45 - 14:15

Industry Theatre

### IT6, Omeros Industry Theatre Session

Educational  
14:30 - 16:00

N103

### E7, CAR-T toxicity and management

**Chairs:**

Joaquín Martínez-López (Spain)

Olaf Penack (Germany)

<b>Cytokine release syndrome</b>	<b>14:30 - 15:00</b>
Susana Rives (Spain)	
<b>Neurotoxicity</b>	<b>15:00 - 15:30</b>
Miguel-Angel Perales (United States)	
<b>EBMT recommendations</b>	<b>15:30 - 16:00</b>
Ibrahim Yakoub-Agha (France)	

Workshop  
14:30 - 16:00

Hall A (Exhibition Area)

### W10, Pretransplant risk management for allogeneic HSCT recipients and donors

**Chairs:**

Adrián Alegre (Spain)

Maria Gilleece (United Kingdom)

<b>Patient infectious risk factors</b>	<b>14:30 - 15:00</b>
Simone Cesaro (Italy)	
<b>Patient comorbidity and organ issues</b>	<b>15:00 - 15:30</b>
Jaime Sanz Caballer (Spain)	
<b>Donor issues that may pose a risk for themselves or for the patients</b>	<b>15:30 - 16:00</b>
Nina Worel (Austria)	

## Scientific Programme

Oral Session  
14:30 - 16:00

Hall B (Exhibition Area)

### OS8, Oral session

Educational  
14:30 - 16:00

N105

### E8, Allogeneic transplantation from family donors

#### Chairs:

Marie Robin (France)  
Antònia Sampol (Spain)

<b>Chinese experience on matched siblings vs. haploidentical</b> Xiaojun Huang (China)	<b>14:30 - 15:00</b>
<b>Matched siblings vs. haploidentical in AML</b> Arnon Nagler (Israel)	<b>15:00 - 15:30</b>
<b>Matched siblings vs. haploidentical in lymphoma</b> Didier Blaise (France)	<b>15:30 - 16:00</b>

Paediatric Day  
14:30 - 16:00

N101

### Paediatrics3, Paediatrics Diseases Oral Session

Multi-stakeholder Forum on Innovative Cellular Therapies  
14:30 - 15:00

Sala Retiro

### MF5, Multi-stakeholder Forum on Innovative Cellular Therapies: Keynote Lecture

#### Chairs:

Rafael Duarte (Spain)

<b>The real-life experience on pricing and access to CAR T therapy in the USA</b> Inmaculada Hernández Delso (United States)	<b>14:30 - 15:00</b>
---	----------------------

Quality Management  
14:30 - 15:30

Sala Colón

### QM6, Auditing more than JACIE

#### Chairs:

Sarah Holtby (United Kingdom)

<b>Introduction</b> Olga López Villar (Spain)	<b>14:30 - 14:45</b>
--	----------------------

## Scientific Programme

<b>Spain / UK</b> Olga López Villar (Spain) Anne Emmett (United Kingdom)	<b>14:45 - 15:00</b>
<b>The Netherlands / Turkey</b> Nick van Sinderen (Netherlands) Ilknur Kozanoglu (Turkey)	<b>15:00 - 15:15</b>
<b>Italy / Belgium</b> Renza Monteleone (Italy) Phuong Huynh (Belgium)	<b>15:15 - 15:30</b>

Nurses Group  
14:30 - 16:00

N107

### NG18, Oral session 4

#### Chairs:

Klara Kabatova Maxova (Czech Republic)  
Begoña de Andrés Gimeno (Spain)

<b>REDUCING ACCIDENTAL FALLS CAUSED BY ORTHOSTATIC HYPOTENSION IN BONE MARROW TRANSPLANT RECIPIENTS</b> <u>Liya Katzir</u> (Israel)	<b>14:30 - 14:48</b>
<b>PREVALENCE, PREDICTORS AND OUTCOMES OF CLABSI AMONG HSCT PATIENTS</b> <u>Jedidah L.M. Lieow</u> , Pin Yan Tan, Yee Mei Lee, Mary Jeanette Jacinto Ignacio (Singapore)	<b>14:48 - 15:06</b>
<b>AT-HOME MANAGEMENT IN AN ALLOGENEIC STEM CELL TRANSPLANTATION DURING IMMEDIATE POST-TRANSPLANTATION PHASE</b> <u>Gloria Garcia</u> , Cristina Gallego, Pilar Ayora, Montserrat Valverde, Lourdes Corominas, Gonzalo Gutierrez, Francesc Fernandez (Spain)	<b>15:06 - 15:24</b>
<b>CREATION OF THE LABMT NURSES GROUP</b>	<b>15:24 - 15:42</b>
<b>THE EFFECT OF MOTIVATIONAL INTERVIEW PERFORMED AFTER STEM CELL TRANSPLANTATION ON SEXUAL EXPERIENCE, SEXUAL SELF- AWARENESS AND SEXUAL SELF-EFFICACY</b>	<b>15:42 - 16:00</b>

Nurses Group  
14:30 - 16:00

N109

### NG19, How do I become an expert?

#### Chairs:

Alberto Castagna (Italy)  
Marta Irala Rivero (Spain)

<b>Sexual function assessment in care</b> Jacqui Stringer (United Kingdom)	<b>14:30 - 15:00</b>
<b>Late effects: Implementation of guidelines</b> Michelle Kenyon (United Kingdom)	<b>15:00 - 15:30</b>

## Scientific Programme

**How to conduct a comprehensive cGVHD assessment?** **15:30 - 16:00**  
John Murray (United Kingdom)

Nurses Group  
14:30 - 16:00

N111

### NG20, Back to basics: How can I improve my skills?

#### Chairs:

Eugenia Trigos Arjona (Spain)  
Cristina Hernández García (Spain)

**Oral care during inpatient hematopoietic cell transplantation** **14:30 - 14:50**  
Nathaniel Simon Triester (United States)

**Recognising sepsis** **14:50 - 15:10**  
Jan Styczynski (Poland)

**CVC management** **15:10 - 15:35**  
Emilian Snarski (Poland)

**Tumor lysis** **15:35 - 16:00**  
Janet Baker (United Kingdom)

Special Session  
14:30 - 16:00

Sala Neptuno

### SS6, Global Committee Session - The impact of infections on HSCT performance worldwide

#### Chairs:

Norbert-Claude Gorin (France)  
Nicolaus Kröger (Germany)

**Introduction** **14:30 - 14:33**  
Norbert-Claude Gorin (France)

**Impact (known or potential) of community respiratory virus infections on the outcome(s) of recipients of an allogeneic HSCT or CAR T-cell therapy** **14:33 - 14:50**  
Rodrigo Martino (Spain)

**Tropical diseases and HSCT** **14:50 - 15:07**  
Francesca Norman (Spain)

**Parasitic infections in HSCT** **15:07 - 15:24**  
Gregorio Jaimovich (Argentina)

**Impact of infections in Asia** **15:24 - 15:41**  
Alok Srivastava (India)

**Particularities of infections in limited-resource countries** **15:41 - 15:58**  
Asma Quessar (Morocco)

## Scientific Programme

**Conclusions** **15:58 - 16:00**  
Nicolaus Kröger (Germany)

Pharmacists Day N113  
14:30 - 16:00

### Pharm4, Update infectious diseases in HSCT

#### Chairs:

Erik van Maarseveen (Netherlands)  
Agnès Bonnin (France)

**What's new in antivirals?** **14:30 - 14:50**  
Per Ljungman (Sweden)

**What is new in vaccines? The Dutch guidelines for HSCT patients** **14:50 - 15:10**  
Anke Bruns (Netherlands)

**What's new in Antifungals?** **15:10 - 15:30**  
Kim van der Elst (Netherlands)

**The effect of antibiotics on the microbiome in HSCT patients: Is it relevant?** **15:30 - 15:50**  
Florent Malard (France)

**Discussion** **15:50 - 16:00**

Data Management N117  
14:30 - 15:10

### DM10, Education session 10

**Hematopoietic Cell Transplantation-Comorbidity Index "Sorrer Score"** **14:30 - 15:10**  
Bronwen Shaw (United States)

Data Management N118  
14:30 - 16:00

### DM19, Training session 2 (pre-registration required)

**MACRO Reports** **14:30 - 16:00**  
Silvia Zaccagnino (United Kingdom)

## Scientific Programme

Working Party Session  
14:30 - 16:00

N115

### LWP, Lymphoma Working Party Session

#### Chairs:

Silvia Montoto (United Kingdom)  
Peter Dreger (Germany)

<b>Welcome and introduction</b>	<b>14:30 - 14:35</b>
Silvia Montoto (United Kingdom)	
<b>Highlights of the LWP activity: Allogeneic transplantation for DLBCL in the CART era: the EBMT-CIBMTR position</b>	<b>14:35 - 14:45</b>
Peter Dreger (Germany)	
<b>LWP Educational Course 2019</b>	<b>14:45 - 14:50</b>
Anna Sureda (Spain)	
<b>Presentation of Jian-Jian Luan Award winner</b>	<b>14:50 - 14:55</b>
Silvia Montoto (United Kingdom)	
<b>Lecture of the Jian-jian Luan Award abstract</b>	<b>14:55 - 15:05</b>
<b>LWP Keynote debate: Relapsed MCL - Should we transplant or continue on new drugs?</b>	
<b>Case presentation</b>	<b>15:05 - 15:15</b>
Silvia Montoto (United Kingdom)	
<b>Transplant</b>	<b>15:15 - 15:30</b>
Olivier Hermine (France)	
<b>New drugs</b>	<b>15:30 - 15:45</b>
Marek Trnety (Czech Republic)	
<b>Patient's perspective and discussion</b>	<b>15:45 - 16:00</b>
Natacha Bolaños (Spain)	

Patient Advocacy Sessions  
14:30 - 16:00

A9.13

### PFD6, Patient Advocacy sessions: Different perspectives on CAR T

#### Chairs:

Guy Bouguet (France)  
Bregje Verhoeven (Netherlands)

<b>A dive into a patient's experience</b>	<b>14:30 - 14:35</b>
<b>Nurse's perspective - What are the changes needed in daily practice?</b>	<b>14:35 - 14:50</b>
Rose Ellard (United Kingdom)	
<b>HTA view on reimbursement: A Dutch perspective - Patience for the patient</b>	<b>14:50 - 15:05</b>
Amr Makady (Netherlands)	
<b>A payer's perspective</b>	<b>15:05 - 15:20</b>



## Scientific Programme

<b>Patient advocate's perspective - Setting the right expectations</b> Natacha Bolaños (Spain)	<b>15:20 - 15:35</b>
<b>Discussion</b>	<b>15:35 - 16:00</b>

Special Session  
14:30 - 15:45

Industry Theatre

### SS7, Young Ambassadors: Jeopardy session

#### Chairs:

Alessandro di Gangi (Italy)  
Eleni Gavriilaki (Greece)  
Alexandra Gómez Arteaga (United States)

<b>Introduction</b>	<b>14:30 - 14:40</b>
<b>Jeopardy</b>	<b>14:40 - 15:45</b>

Multi-stakeholder Forum on Innovative Cellular Therapies  
15:00 - 16:00

Sala Retiro

### MF6, Multi-stakeholder Forum on Innovative Cellular Therapies: How are new cellular therapies being rolled out?

#### Chairs:

Mohamad Mohty (France)  
Jorge Sierra (Spain)

<b>France</b> Ibrahim Yakoub-Agha (France)	<b>15:00 - 15:15</b>
<b>England - JACIE and NHSE collaboration</b> Kim Orchard (United Kingdom)	<b>15:15 - 15:30</b>
<b>Netherlands - How are cellular therapies translated from academia to industrial partners. Pitfalls and opportunities</b> Jürgen Kuball (Netherlands)	<b>15:30 - 15:45</b>
<b>Switzerland</b> Jörg Halter (Switzerland)	<b>15:45 - 16:00</b>

Data Management  
15:20 - 16:00

N117

### DM11, Education session 11

#### Chairs:

Jorinde Hoogenboom (Netherlands)

<b>CAR T-cells - Moving into the mainstream</b> Reuben Benjamin (United Kingdom)	<b>15:20 - 16:00</b>
---	----------------------

## Scientific Programme

Quality Management  
15:30 - 16:00

Sala Colón

### QM7, Oral Abstracts

**Chairs:**

Carlos Torrico (Spain)

<b>Abstract 1</b>	<b>15:30 - 15:40</b>
<b>Abstract 2</b>	<b>15:40 - 15:50</b>
<b>Abstract 3</b>	<b>15:50 - 16:00</b>

Industrial Theatre  
16:00 - 16:30

Industry Theatre

### IT7, Bluebirdbio Industry Theatre Session

Educational  
16:30 - 18:00

N103

### E9, Landscape for CLL management in 2020

**Chairs:**

Peter Dreger (Germany)

José A. García-Marco (Spain)

<b>Dissecting CLL at a single-cell level - Implications for therapy and outcome</b> Catherine Wu (United States)	<b>16:30 - 17:00</b>
<b>The broadening landscape of targets and therapeutic options for CLL</b> Michael Hallek (Germany)	<b>17:00 - 17:30</b>
<b>HSCT and cellular therapy for CLL in 2020</b> John Gribben (United Kingdom)	<b>17:30 - 18:00</b>

Educational  
16:30 - 18:00

Hall A (Exhibition Area)

### E10, Therapies to bring resistant acute leukemia into HSCT

**Chairs:**

Arnon Nagler (Israel)

Jorge Sierra (Spain)

<b>Novel targeted therapy before HSCT for AML/MDS</b> Guillermo García-Manero (United States)	<b>16:30 - 17:00</b>
<b>New conditioning regimen for relapsed acute leukemia</b> Ali Bazarbachi (Lebanon)	<b>17:00 - 17:30</b>

## Scientific Programme

**Sequential therapy for AML** **17:30 - 18:00**  
Rémy Duléry (France)

Oral Session  
16:30 - 18:00

Hall B (Exhibition Area)

### OS9, Oral session

Working Party Session  
16:30 - 18:00

N105

### CTIWP, Cellular Therapy and Immunobiology Working Party Session

#### Chairs:

Christian Chabannon (France)  
Annalisa Ruggeri (France)

**Presentation of CTIWP activities** **16:30 - 16:40**  
Christian Chabannon (France)

**Presentation of the Jon J. van Rood Award** **16:40 - 16:50**  
Christian Chabannon (France)  
Hans-Jochem Kolb (Germany)

**Jon J. van Rood award winning abstract presentation** **16:50 - 17:10**

**Use of RNAseq for immune monitoring** **17:10 - 17:35**  
Jean-Jacques Fournié (France)

**In vivo reconstitution dynamics of human HSPC after HSC gene therapy** **17:35 - 18:00**  
Serena Scala (Italy)

Paediatric Day  
16:30 - 18:00

N101

### Paediatrics4, Inborn Errors Oral Session

Multi-stakeholder Forum on Innovative Cellular Therapies  
16:30 - 17:20

Sala Retiro

### MF7, Multi-stakeholder Forum on Innovative Cellular Therapies: Managing expectations - access to treatment

#### Chairs:

Bregje Verhoeven (Netherlands)  
Anna Sureda (Spain)

**Where's the access bottleneck: centres, industry, authorities?** **16:30 - 16:55**  
Joaquín Martínez-López (Spain)

## Scientific Programme

**Patients who missed their CAR - failed intention to treat in real-life?** **16:55 - 17:20**  
Antonio Pagliuca (United Kingdom)

Quality Management  
16:30 - 17:30

Sala Colón

### QM8, QM and future development in HSCT

#### Chairs:

Almudena de Laiglesia (Spain)

**TRANSDOSE EU Project** **16:30 - 16:45**  
Suzanna M. van Walraven (Netherlands)

**EuroGTPII: An interactive assessment tool for risk assessment of new processes** **16:45 - 17:00**  
Aurora Vassanelli (Italy)

**CAR T accreditation: What can you expect?** **17:00 - 17:15**  
Mara Magri (Italy)

**Questions & Answers** **17:15 - 17:30**

Nurses Group  
16:30 - 18:00

N107

### NG21, Care of the caregivers

#### Chairs:

Diana Comerford (United Kingdom)  
Laura Vicente Izquierdo (Spain)

**Empowering the caregivers: Social worker** **16:30 - 17:00**  
Rebecca Parker (United Kingdom)

**Implementation of a tool to support parents of your patients** **17:00 - 17:30**  
Marijke Quaghebeur (Belgium)

**Ambulatory transplants patients: Caregivers role** **17:30 - 18:00**  
Audrey Casabona-Navarro (France)

Nurses Group  
16:30 - 18:00

N109

### NG22, Infections

#### Chairs:

Iris Agreiter (Ireland)  
Francisco Xosé Román Losada (Spain)

**How to find a fungal infection** **16:30 - 16:50**  
Toine Mercier (Belgium)

## Scientific Programme

<b>CMV</b> Patrice Ceballos (France)	<b>16:50 - 17:10</b>
<b>Polyoma virus</b> Marta Canesi (Italy)	<b>17:10 - 17:35</b>
<b>Nursing leadership in antimicrobial stewardship interventions</b> Enrique Castro-Sánchez (United Kingdom)	<b>17:35 - 18:00</b>

Nurses Group  
16:30 - 18:00

N111

### NG23, Quality processes in JACIE

#### Chairs:

Marjola Gjergji (Italy)  
Alba Fernández-Arroyo (Spain)

<b>Quality indicators for nurses</b> Louise McNamara (United Kingdom)	<b>16:30 - 17:00</b>
<b>JACIE: What's new?</b> Eoin McGrath (Spain)	<b>17:00 - 17:30</b>
<b>What is the nurse role as JACIE inspector?</b> Eugenia Trigo Arjona (Spain)	<b>17:30 - 18:00</b>

General  
16:30 - 18:00

Sala Neptuno

### GS3, General Assembly

#### Chairs:

Nicolaus Kröger (Germany)  
Harry Dolstra (Netherlands)  
Rafael Duarte (Spain)

<b>President's Report</b> Nicolaus Kröger (Germany)	<b>16:30 - 16:50</b>
<b>Treasurer's Financial Report</b> Harry Dolstra (Netherlands)	<b>16:50 - 17:05</b>
<b>Secretary's Report</b> Rafael Duarte (Spain)	<b>17:05 - 17:20</b>
<b>2020 Election Results</b> Rafael Duarte (Spain)	<b>17:20 - 17:25</b>
<b>Outgoing Board Members</b> Nicolaus Kröger (Germany)	<b>17:25 - 17:30</b>

## Scientific Programme

Pharmacists Day  
16:30 - 18:00

N113

### Pharm5, Round table discussions (at the Meet the Expert rooms)

**Chairs:**

Claudia Langebrake (Germany)

**Round table discussions - Rooms A10.12, A10.13, A10.15**

**16:30 - 17:30**

**JACIE for pharmacists in practice**

Tiene Bauters (Belgium)

**The role of the aseptic pharmacist in gene therapy clinical trials**

Anne Black (United Kingdom)

**Drug interactions with complementary and alternatives herbs and medicines**

Tine van Nieuwenhuyse (Belgium)

**Summary of groups - Room N113**

**17:30 - 18:00**

Data Management  
16:30 - 17:10

N117

### DM12, Education session 12

**Chairs:**

Helen Baldomero (Switzerland)

**Discussion forum - Being a data manager: practical issues**

**16:30 - 17:10**

Julia Lee (United Kingdom)

Juana Schwartz Mota (Spain)

Steffie van der Werf (Netherlands)

Data Management  
16:30 - 17:30

N118

### DM20, Training session 2 (continued) (pre-registration required)

**MACRO Reports**

**16:30 - 17:30**

Silvia Zaccagnino (United Kingdom)

Working Party Session  
16:30 - 18:00

N115

### SAAWP, Severe Aplastic Anaemia Working Party Session

**Chairs:**

Régis Peffault de Latour (France)

Antonio Risitano (Italy)

## Scientific Programme

<b>Introduction</b> Régis Peffault de Latour (France)	<b>16:30 - 16:35</b>
<b>Registry report</b> Antonio Risitano (Italy)	<b>16:35 - 16:40</b>
<b>Prospective randomized studies</b>	
<b>RACE clinical trial</b> Antonio Risitano (Italy)	<b>16:40 - 16:50</b>
<b>The EMAA-Study: Evaluating the significance of Eltrombopag in moderate aplastic anemia</b> Britta Hoechsmann (Germany)	<b>16:50 - 17:00</b>
<b>Haplo-identical BMT and aplastic anemia: past and future</b> Andrea Bacigalupo (Italy)	<b>17:00 - 17:30</b>
<b>Retrospective studies</b>	
<b>Stem cell transplantation for Blackfan-Diamond Anemia: A retrospective study of EBMT SAAWP</b> Maurizio Miano (Italy)	<b>17:30 - 17:45</b>
<b>Upfront MUD transplantation for patients with idiopathic aplastic anemia</b> Audrey Petit (France)	<b>17:45 - 18:00</b>

Patient Advocacy Sessions  
16:30 - 18:00

A9.13

### **PFD7, Patient Advocacy sessions: Patient Reported Outcomes. A gap to fill**

#### **Chairs:**

Natacha Bolaños (Spain)  
Hélène Schoemans (Belgium)

<b>Clinical trials and PRO. Introduction to PRO, analysing the data and challenges</b> Raúl Córdoba Mascuñano (Spain)	<b>16:30 - 16:45</b>
<b>The use of real world data to support registers</b> John New (United Kingdom)	<b>16:45 - 17:00</b>
<b>The clinicians perspective: why do we need PRO? Possibilities and challenges</b> Hélène Schoemans (Belgium)	<b>17:00 - 17:15</b>
<b>Introducing the patient's experience with PRO</b>	<b>17:15 - 17:30</b>
<b>Discussion</b>	<b>17:30 - 18:00</b>

46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT),  
22 - 25 March 2020,  
Madrid, Spain

## Scientific Programme

Multi-stakeholder Forum on Innovative Cellular Therapies  
17:20 - 17:30

Sala Retiro

### **MF8, Closing - 1st Multi-stakeholder Forum on Innovative Cellular Therapies**

#### **Chairs:**

Jürgen Kuball (Netherlands)

#### **Closing remarks**

**17:20 - 17:30**

Jürgen Kuball (Netherlands)

Quality Management  
17:30 - 18:00

Sala Colón

### **QM9, Cases**

#### **Case 1**

**17:30 - 17:45**

#### **Case 2**

**17:45 - 18:00**



## Scientific Programme

### Wednesday, 25 March 2020

---

Meet the Expert  
08:00 - 09:00

Meet the Expert Rooms

#### **MTE-16, Meet the Expert session 16 - Room A10.05**

**HSCT and gene therapy in inherited metabolic diseases**  
Robert Wynn (United Kingdom)

**08:00 - 09:00**

Meet the Expert  
08:00 - 09:00

Meet the Expert Rooms

#### **MTE-17, Meet the Expert session 17 - Room A10.06**

**Current challenges facing emerging donor registries in 2020**  
Mahmoud Aljurf (Saudi Arabia)

**08:00 - 09:00**

Meet the Expert  
08:00 - 09:00

Meet the Expert Rooms

#### **MTE-18, Meet the Expert session 18 - Room A10.07**

**HSCT indications in paediatric MDS**  
Charlotte Niemeyer (Germany)

**08:00 - 09:00**

Meet the Expert  
08:00 - 09:00

Meet the Expert Rooms

#### **MTE-19, Meet the Expert session 19 - Room A10.12**

**Ex vivo cellular manipulation and therapy as the platform of choice for allogeneic HSCT in 2020**  
Stephan Mielke (Sweden)

**08:00 - 09:00**

Meet the Expert  
08:00 - 09:00

Meet the Expert Rooms

#### **MTE-20, Meet the Expert session 20 - Room A10.13**

**Current role of mesenchymal stromal cells in HSCT**  
Peter Bader (Germany)

**08:00 - 09:00**

## Scientific Programme

Meet the Expert  
08:00 - 09:00

Meet the Expert Rooms

### MTE-21, Meet the Expert session 21 - Room A10.15

**HSCT in MS and immune-mediated neurological diseases: patient selection and follow-up**

**08:00 - 09:00**

Basil Sharrack (United Kingdom)

Meet the Expert  
08:00 - 09:00

Meet the Expert Rooms

### MTE-15, Meet the Expert Session 15 - Room A10.01

**Fungal infections in HSCT recipients - the challenges in 2020**

**08:00 - 09:00**

Livio Pagano (Italy)

Plenary Session  
09:00 - 10:30

N103

### P4, New developments in the field of CAR T-cell therapy

#### Chairs:

Christian Chabannon (France)  
Álvaro Urbano-Ispizua (Spain)

**An independent evaluation of the economic value of the two approved CAR T-cells**

**09:00 - 09:22**

John K. Lin (United States)

**Safe and potent anti-CD19 CAR T-cell therapy - An experience from China**

**09:22 - 09:44**

Zhitao Ying (China)

**CAR T-cell technology and strategy for solid tumors**

**09:44 - 10:06**

Hinrich Abken (Germany)

**Future of CAR T-cell therapies**

**10:06 - 10:28**

Stéphane Depil (France)

Educational  
09:00 - 10:30

N105

### E11, Management of early complications in an ambulatory/outpatient setting

#### Chairs:

Francesc Fernández-Avilés (Spain)  
Tapani Ruutu (Finland)

**Early infections**

**09:00 - 09:22**

Jan Styczynski (Poland)

**Organ toxicity**

**09:22 - 09:44**

Gerhard Hildebrandt (United States)

## Scientific Programme

<b>Acute GVHD</b> Zinaida Peric (Croatia)	<b>09:44 - 10:06</b>
<b>The Hospital Clínic experience</b> Gonzalo Gutiérrez-García (Spain)	<b>10:06 - 10:28</b>

Workshop  
09:00 - 10:30

N101

### W11, Battling acute leukemia relapse after allogeneic HSCT

**Chairs:**

David Valcárcel Ferreiras (Spain)  
Thomas Cluzeau (France)

<b>CAR T-cells</b> Mohamad Mohty (France)	<b>09:00 - 09:30</b>
<b>Maintenance strategies after allogeneic HSCT</b> Charles Craddock (United Kingdom)	<b>09:30 - 10:00</b>
<b>Second allogeneic HSCT</b> Bipin Savani (United States)	<b>10:00 - 10:30</b>

Workshop  
09:00 - 10:30

Sala Retiro

### W12, HSCT for immune modulation of solid organ transplantation

**Chairs:**

Antonio Pérez-Martínez (Spain)  
Petr Sedlacek (Czech Republic)

<b>Basis and opportunities of HSCT as a tool to induce immunotolerance to SOT</b> Megan Sykes (United States)	<b>09:00 - 09:30</b>
<b>HSCT to induce immunotolerance to lung transplantation</b> Paul Szabolcs (United States)	<b>09:30 - 10:00</b>
<b>HSCT to induce immunotolerance to composite tissue transplantation</b> Sebastian Giebel (Poland)	<b>10:00 - 10:30</b>

Special Session  
09:00 - 10:30

Sala Colón

### SS8, EBMT benchmarking - A key quality improvement tool

**Chairs:**

Carlos Solano Vercet (Spain)  
Eoin McGrath (Spain)

## Scientific Programme

<b>Project update</b> John Snowden (United Kingdom)	<b>09:00 - 09:20</b>
<b>Methodological aspects of EBMT benchmarking</b> Hein Putter (Netherlands)	<b>09:20 - 09:40</b>
<b>Results so far</b> Riccardo Saccardi (Italy)	<b>09:40 - 10:00</b>
<b>Next steps - Gaining confidence</b> Kim Orchard (United Kingdom)	<b>10:00 - 10:20</b>
<b>Round table discussion: Will benchmarking replace the need for accreditation?</b>	<b>10:20 - 10:30</b>

Oral Session  
09:00 - 10:30

N107

### OS10, Oral session

Oral Session  
09:00 - 10:30

N109

### OS11, Oral session

Nurses Group  
09:00 - 10:30

N111

## NG24, Nurses Programme: Closing Session

### Chairs:

John Murray (United Kingdom)  
Klara Kabatova Maxova (Czech Republic)

<b>GVHD practical tips</b>	
<b>Eye</b> Sandra Schoenfeld (Switzerland)	<b>09:00 - 09:18</b>
<b>Oral</b> Caroline Bompont (France)	<b>09:18 - 09:36</b>
<b>Cutaneous</b> John Murray (United Kingdom)	<b>09:36 - 09:54</b>
<b>Supportive care and management of gastrointestinal complications in GVHD</b> Lucija Jurisic (Croatia)	<b>09:54 - 10:12</b>
<b>Genital</b> Angela Leather (United Kingdom)	<b>10:12 - 10:30</b>

## Scientific Programme

Oral Session  
09:00 - 10:30

Sala Neptuno

### OS12, Oral session

Oral Session  
09:00 - 10:30

N113

### OS13, Oral session

Special Session  
09:00 - 10:30

N117

### SS9, HARMONY Alliance Project

#### Chairs:

Guillermo Sanz Santillana (Spain)  
Pamela Bacon (Switzerland)

<b>General Overview of the HARMONY Alliance: Progress, achievements and results</b>	<b>09:00 - 09:15</b>
Jesús M. Hernández Rivas (Spain)	
<b>Expected contribution of the EBMT</b>	<b>09:15 - 09:25</b>
Guillermo Sanz Santillana (Spain) Pamela Bacon (Switzerland)	
<b>EBMT participation</b>	<b>09:25 - 09:45</b>
Anna Sureda (Spain)	
<b>HARMONY Research Projects / Outcomes definition</b>	<b>09:45 - 10:00</b>
Lars Bullinger (Germany)	
<b>HARMONY Platform</b>	<b>10:00 - 10:15</b>
Ana Heredia Casanoves (Spain)	
<b>Questions &amp; Answers</b>	<b>10:15 - 10:30</b>

Oral Session  
09:00 - 10:30

N118

### OS14, Oral session

## Scientific Programme

Joint Session  
09:00 - 10:00

N115

### **JS4, Joint session KSBMT: Status of Next Generation Sequencing for indication and monitoring in stem cell transplantation 2020**

**Chairs:**

Nicolaus Kröger (Germany)  
Hoon Kook (Korea, Republic of)

<b>NGS for indication in myeloid malignancies</b>	<b>09:00 - 09:25</b>
Jae-Sook Ahn (Korea, Republic of)	
<b>Discussion</b>	<b>09:25 - 09:30</b>
<b>Disease monitoring post transplant with NGS</b>	<b>09:30 - 09:55</b>
<b>Discussion</b>	<b>09:55 - 10:00</b>

Educational  
11:00 - 12:30

N103

### **E12, Novel immunotherapies in Multiple Myeloma**

**Chairs:**

Jesús San Miguel (Spain)  
Ibrahim Yakoub-Agha (France)

<b>CD38-targeting monoclonal antibodies</b>	<b>11:00 - 11:22</b>
Niels van de Donk (Netherlands)	
<b>Bispecific antibodies and BiTEs</b>	<b>11:22 - 11:44</b>
Hermann Einsele (Germany)	
<b>CAR T-cells</b>	<b>11:44 - 12:06</b>
Noopur Raje (United States)	
<b>How should we position immunotherapies in the changing paradigm of myeloma treatment?</b>	<b>12:06 - 12:28</b>
Meral Beksac (Turkey)	

Educational  
11:00 - 12:30

N105

### **E13, Non-malignant paediatric**

**Chairs:**

Marta González-Vicent (Spain)  
Paul Veys (United Kingdom)

<b>Haplo-identical SCT in hemoglobinopathy: Taking pole position?</b>	<b>11:00 - 11:22</b>
Josu de la Fuente (United Kingdom)	
<b>Mismatched family donors in inherited immune disorders: A new perspective</b>	<b>11:22 - 11:44</b>
Mary A. Slatter (United Kingdom)	

## Scientific Programmes

**HSCT for inherited bone marrow failure syndromes** 11:44 - 12:06  
Cristina Díaz de Heredia (Spain)

**Cord blood HSCT for non-malignant diseases in children** 12:06 - 12:28  
Vanderson Rocha (Brazil)

Workshop  
11:00 - 12:30

N101

### W13, Cellular therapy beyond CAR T-cells

#### Chairs:

José María Moraleda (Spain)  
Fred Falkenburg (Netherlands)

**Gamma-Delta T-cell Therapy** 11:00 - 11:22  
Jürgen Kuball (Netherlands)

**Stem cell derived NK cell Therapy** 11:22 - 11:44  
Harry Dolstra (Netherlands)

**MSC and extracellular vesicles in stem cell transplantation** 11:44 - 12:06  
Fermín Sánchez-Guijo (Spain)

**HLA-mismatched microtransplantation** 12:06 - 12:28  
Huisheng Ai (China)

Workshop  
11:00 - 12:30

Sala Retiro

### W14, Who's the best alternative donor to a matched-sibling?

#### Chairs:

Fabio Ciceri (Italy)  
Maria Jesús Pascual (Spain)

**A matched unrelated donor** 11:00 - 11:22  
Bronwen Shaw (United States)

**A haploidentical donor** 11:22 - 11:44  
Mi Kwon (Spain)

**A cord blood unit** 11:44 - 12:06  
Guillermo Sanz Santillana (Spain)

**Do we have to challenge our current donor hierarchy for patients with hemoglobinopathies?** 12:06 - 12:28  
Selim Corbacioglu (Germany)

## Scientific Programme

Oral Session  
11:00 - 12:30

Sala Colón

### OS15, Oral session

Oral Session  
11:00 - 12:30

N107

### OS16, Oral session

Oral Session  
11:00 - 12:30

N109

### OS17, Oral session

Nurses Group  
11:00 - 12:30

N111

### NG25, Nurses Group Highlights and Summary

#### Chairs:

John Murray (United Kingdom)  
Klara Kabatova Maxova (Czech Republic)

<b>Outreach Presentation</b> Veena Paulson (India)	<b>11:00 - 11:20</b>
<b>Best of the Best: Presentation of NG Abstract prizes</b> John Murray (United Kingdom)	<b>11:20 - 11:40</b>
<b>Highlights from physician's sessions</b> Izaskun Zeberio (Spain)	<b>11:40 - 12:00</b>
<b>Presentation of Prague 2021</b> Klara Kabatova Maxova (Czech Republic)	<b>12:00 - 12:20</b>

Oral Session  
11:00 - 12:30

Sala Neptuno

### OS18, Oral session

Oral Session  
11:00 - 12:30

N113

### OS19, Oral session



## Scientific Programme

Oral Session  
11:00 - 12:30

N117

### OS20, Oral session

Oral Session  
11:00 - 12:30

N118

### OS21, Oral session

Joint Session  
11:00 - 12:00

N115

### JS5, Joint session LABMT

#### Chairs:

Rafael Duarte (Spain)  
Gregorio Jaimovich (Argentina)

**Development opportunities for LABMT and EBMT** **11:00 - 11:20**

Alejandro Madrigal (United Kingdom)  
Amado Karduss (Colombia)

**Accreditation: Experience on implementing the “International Stepwise Accreditation Programme” by JACIE in Latin America** **11:20 - 11:40**

Patricia Abichaín (Argentina)  
Raquel Espada (Spain)

**Round table discussion: How to strengthen EBMT-LABMT cooperation** **11:40 - 12:00**

Special Session  
12:30 - 13:30

N103

### SS10, Best of EBMT 2020

#### Chairs:

Rafael Duarte (Spain)  
Nicolaus Kröger (Germany)

**EBMT 2020 highlights: Adults** **12:30 - 12:50**

Pavel Jindra (Czech Republic)

**EBMT 2020 highlights: Basic** **12:50 - 13:10**

Sergio Querol Giner (Spain)

**EBMT 2020 highlights: Paediatrics** **13:10 - 13:30**

Antonio Pérez-Martínez (Spain)

## Scientific Programme

General  
13:30 - 14:05

N103

### GS4, Closing Ceremony

**Chairs:**

Rafael Duarte (Spain)  
Nicolaus Kröger (Germany)  
Pavel Jindra (Czech Republic)  
Petr Sedlacek (Czech Republic)

<b>Presentation of the Springer Nature Poster Awards</b>	<b>13:30 - 13:35</b>
<b>Local President Madrid 2020 closing remarks</b> Rafael Duarte (Spain)	<b>13:35 - 13:45</b>
<b>Local Co-Presidents for EBMT 2021 Prague: Welcome</b> Pavel Jindra (Czech Republic) Petr Sedlacek (Czech Republic)	<b>13:45 - 13:55</b>
<b>EBMT President closing remarks</b> Nicolaus Kröger (Germany)	<b>13:55 - 14:05</b>